 
 
 
Drug Substance O laparib (AZD2281, KU-0059436), Durvalumab ( MEDI 4736) 
Study Number  ESR-15-11311/EPM 6724 
Version Number 6.0 
Date 14Jun2021 
 
[STUDY_ID_REMOVED] 
 
PHASE II MULTICEN TER ST UDY OF DURVALUM AB 
(MEDI4736) AND OLAPARIB IN PLATI NUM TREA TED 
ADVANCED TRIPLE NEGATI VE BREAST CANCER - DORA 
 
 
STUDY  CHA IRS 
Dr. Rebecca A. Dent 
 
Senior Consultant 
National Cancer Center Singapor e 
rebecca.dent@duke-nus.edu.sg  
 
Dr. S arah Sa mmons 
 
Duke Cancer I nstitute  
 Duke Univer sity Med ical Cent er 
 
Sarah.Sa mmons@duke.edu  
 
 
  
 
 
CORRELA TIVE SC IENCE CHAIR  
Dr. Tira J. T an 
 
Consu ltant 
 
Nation al Cancer Center Singapore 
 
Tira.Ta n@uhn. ca 
 
 
DCRI  PROJECT LEADER  
Kelly M undy 
 
Duke Clin ical Research Institute 
 
kelly.mund y@duke.edu  
 
 
 
  
 
  
 
1(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advan ced triple nega tive breast cancer 
V 6.0 
2(80)  
  
 
 
TABLE OF  CON TENTS PAGE  
 
 
TABLE O F CO NTEN TS................................ ................................ ................................ ............................. 2  
 
LIST OF TA BLES ................................ ................................ ................................ .............................. 5  
 
LIST OF FIGURES ................................ ................................ ................................ ............................. 5  
 
1 Re: IND 133602 / A0 005 • DO RA................................ ................................ ................................ .... 6 
 
2 Da niel K. Be njamin, MD, MPH, PhD ................................ ................................ .............................. . 7 
 
LIST OF ABBRE VIATIO NS AND DEF INITION OF TERMS ................................ ............................. 8  
 
1 Intro duction ............................... ................................ ................................ ................................ . 13 
 1.1 Drug efficacy, safety and dosing: background ............................... ................................ ................... .14 
 1.1.1 Olaparib in t he context of breast cancer ............................... ................................ ................................  14 
 1.1.2 Preclinical experience with olaparib ............................... ................................ ................................ ....... 15 
 1.1.3 Toxicology and safety pharmacology summary for olaparib ............................... ................................ .. 15 
 1.1.4 Clinical experience with olaparib ............................... ................................ ................................ ............  15 
 1.1.5 Clinical experience with durvalumab ............................... ................................ ................................ ...... 18 
 1.2 Research hypothesis ............................... ................................ ................................ .........................18  
 1.3 Rationale for condu cting this study ............................... ................................ ................................ ...18 
 1.4 Benefit/risk and ethical assessment ............................... ................................ ................................ ..19 
 1.5 Rationale for drug dosing in this study............................... ................................ .............................. .20 
 1.5.1 Rationale for dose of olaparib............................... ................................ ................................ .................  20 
 1.5.2 Rationale for Durvalumab fixed dosing............................... ................................ ................................ ... 20 
 1.5.3 Rationale for dose of olaparib in c ombination with durvalumab ............................... ...........................  21 
2 S tudy Objec tives ................................ ................................ ................................ ......................... 22 
2.1 Primary object ive................................ ................................ ............................... ..............................22  
2.2 Seconda ry objectives ............................... ................................ ................................. .......................22  
2.3 E xploratory object ives............................... ................................ ................................. ......................22  
 
3  Study design ............................... ................................ ................................ ............................... . 24 
 3.1 Overall study structure and flow chart............................... ................................ .............................. .24 
 3.2 Rationale for study design, doses and control groups............................... ................................ ........ .25 
 3.3 Rationale for prior treatment with platinum............................... ................................ ..................... .25 
 3.4 Inclusion Criteria............................... ................................ ................................ ...............................26  
 3.5 Exclusion Criteria ............................... ................................ ................................ ..............................28  
 3.6 Restrictions during the study ............................... ................................ ................................ ............ .30 
3.6.1 Pregnancy/Br east feeding ................................ ............................... ................................. ....................... 30 
3.6.2 Surge ry ............................... ................................. ................................ ............................... .................... 32 
3.6.3 Radiation ................................ ............................... ................................ ................................. ................ 33 
3.6.4 Administration of other anti- cancer agents ................................ ............................... ............................ 33 
3.6.5 Bl ood don ation................................ ............................... ................................. ................................ ....... 33 
3.6.6 Other concom itant treatment and med ications ................................ ............................... .....................  33 
3.7 Da ta Mana gem ent ................................ ................................ ................................ ...........................34  
3.8 Eval uation and calculation o f variables ................................ ............................... .............................. 35 
3.9 Ca lculatio n or derivation of efficacy vari able(s) ............................... ................................ ................. .35 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advan ced triple nega tive breast cancer 
V 6.0 
3(80)  
  
3.9.1 Ev aluation of Best O verall Response ................................ ............................... ................................ ....... 36 
 
4 Stud y procedures and assessments ............................... ................................ ............................. . 36 
 4.1 Subject enrollment and randomization ............................... ................................ ............................. .36 
 4.1.1 Informed consent ............................... ................................ ................................ ................................ .... 36 
 4.1.2 Screening Procedures............................... ................................ ................................ ..............................  37 
 4.1.5 Post-platinum chemotherapy tumor evaluation............................... ................................ .......................  38 
 4.1.6 Procedures for randomization............................... ................................ ................................ ................  39 
 4.1.7 Procedures for handling ineligible or screen-fail subjects ............................... ................................ ...... 39 
 4.2 Treatments ............................... ................................ ................................ ................................ .......39 
 4.2.1 Identity of investigational product(s)............................... ................................ ................................ ...... 39 
 4.2.2 Olaparib ............................... ................................ ................................ ................................ ...................  40 
 4.2.3 Olaparib: doses and treatment regimens ............................... ................................ ...............................  40 
 4.2.4 Management of toxicity of olaparib ............................... ................................ ................................ ....... 40 
 4.2.5 Durvalumab ............................... ................................ ................................ ................................ .............  44 
 4.2.6 Durvalumab: drug preparation ............................... ................................ ................................ ...............  44 
 4.2.7 Durvalumab: Doses and treatment regimens ............................... ................................ .........................  45 
 4.2.8 Durvalumab: monitoring of dose administration ............................... ................................ ...................  46 
 4.2.9 Management of toxicity of durvalumab ............................... ................................ .................................  47 
4.2.10 Labe ling ................................ ............................... ................................. ............................... ............... 49 
4.2.11 Sto rage ............................... ................................. ................................ ............................... ................ 49 
4.2.12 Treatment compliance ............................... ................................. ............................... ........................ 49 
4.2.13 A ccountability ................................ ............................... ................................ ................................. .... 50 
4.3 Disc ontinuation of study treatment ................................ ................................ ..................................51  
4.4 Proc edures for discontinuatio n of a subject from in vestigati onal product................................ ......... .52 
4.5 Co llectio n of st udy vari able s............................... ................................. ................................ ............ .52 
4.5.1 Du ring olaparib or o laparib and durv alum ab maintenance ................................ ................................ ... 52 
4.5.2 Subsequent v isits............................... ................................. ............................... ................................ ..... 53 
4.5.3 End-of-st udy v isit ............................... ................................. ............................... ................................ .... 54 
4.6 Biological sam pling proc edures ................................ ................................ ............................... ........ .55 
4.6.1 Ha n dling, storage an d destru ction o f biolog ical samp les ............................... ................................ ....... 56 
4.6.2 Biom arker samp les................................ ................................ ................................ ................................. 56 
4.6.3 Withdraw al of infor med consent for donate d biomarke r samp les ................................ .......................  56 
4.7 Follow-u p proc edures ............................... ................................ ................................. ......................5 6 
4.8 Effic acy ................................ ................................ ............................... ................................. ........... .57 
4.8.1 Efficacy  outcome me asures ................................ ................................ ............................... .................... 57 
 
5 S afety ................................ ................................ ................................ ................................ ......... 6 0 
 5.1 Definition of adverse events............................... ................................ ................................ ............. .60 
 5.2 Definitions of serious adverse event ............................... ................................ ................................ ..60 
 5.3 Definition of adverse events of special interest (AESI) ............................... ................................ ........61 
 5.4 Recording of adverse events............................... ................................ ................................ ............. .61 
5.4.1 Time perio d for co llect ion o f adv erse events and serious adverse e vents............................... ............. 63  
5.5 Follow-u p of unres olved adve rse events ............................... ................................. .......................... .63 
5.6 Advers e events based on signs and sympto ms ................................ ............................... .................. .63 
5.7 Advers e events based on examinations and tests ............................... ................................. ............ .63 
5.8 Disea se progres sion ............................... ................................ ................................. .........................6 4 
5.9 New c ancers ................................ ................................ ................................ ............................... .....64 
5.10 Lac k of efficacy ............................... ................................. ............................... .................................64  
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advan ced triple nega tive breast cancer 
V 6.0 
4(80)  
  
5.11 Dea ths ................................ ................................ ............................... ................................ ............. .64 
5.12 Ot her events requiring reporting ............................... ................................. ............................... .......64 
5.12.1 Pre gnan cy ................................ ................................ ................................ ................................ .......... 64 
5.12.5 Reporting o f serious a dverse e vents ................................ ............................... ................................ .. 65  
6  Ethical and regulatory requireme nts............................... ................................ ............................ . 66 
 6.1 Ethical condu ct of the study ............................... ................................ ................................ ............. .66 
 6.2 Subject data protection............................... ................................ ................................ ..................... 67 
 6.3 Ethics and regulatory review ............................... ................................ ................................ ............ .67 
 6.4 Informed consent ............................... ................................ ................................ ............................. 67 
 6.5 Changes to the protocol and informed consent form ............................... ................................ ........ .67 
 6.6 Protocol deviations ............................... ................................ ................................ ........................... 68 
 6.7 Publication policy............................... ................................ ................................ .............................. 68 
7 Sta tistical Methods and s ample size determ ination ................................ ................................ ..... 68 
7.1 Stat istical analyses and determi nation of sample size ................................ ............................... ........68 
7.2 Safe ty data review committee ................................ ................................ ................................ ......... .68 
 
8 LIST OF REFEREN CES ................................ ................................ ................................ .................... 69 
 
9 APPENDICES ................................ ................................ ................................ ................................ 72 
 
Appendix A : Schedule of Assessmen ts................................ ................................ ................................ 72 
 
Appendix B : Known Str ong in Vivo Inhib itors or Induc ers of CYP3A ................................ .................... 75 
 
Appendix C : Adverse Event A ssessment of Causa lity ................................ ................................ .......... 76 
 
Appendix D : Under 3 0 kg Total Body Weight Du rvalumab Do se calcula tion ................................ ........ 77 
 
Appendix E : A ssessment of Po ssible Drug Induced Li ver Injury ................................ ........................... 78 
 
Appendix F : Toxicity Manageme nt Guidelines (Vers ion – 17Oct2019) ................................ ................ . 79 
 
Appendix G : Addi tional re quired tests (Kor ean sites ONL Y) ................................ .............................. 80 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advan ced triple nega tive breast cancer 
V 6.0 
5(80)  
  
 
LIST OF TABLES 
 
 
 
Table 1: Highly E ffectivea Meth ods of Con traception  31 
Table 2: Identity of Inv estiga tional Product  41 
Table 3: Durvalumab hold and infusi on times   47 
Table 4: Durvalumab dose modifica tion due to toxicit y   48 
Table 5: Ma nagement of immune-relat ed adverse ev ents   49 
Table 6. Hematology Labo ratory Tests   55 
Table 7. C linical chemistry (Serum or Pl asma) Laboratory Test s   56 
Table 8: Volume of blood to be drawn from each su bject   57 
Table 9: R esponse criteri a   58 
Table 10: Definition of best overall r esponse as per RECI ST criteri a   60 
   
 
 
 
LIST OF FIGURES 
  
 
Figure  1: Study Sche ma   24 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advan ced triple nega tive breast cancer 
V 6.0 
6(80)  
  
 
 
 
July 02, 2018  
 
Food and Drug Administ ration 
 
Center for Drug Evaluation and Res earch Division 
of Cardiovascula r and Re nal Products 5901- B 
Ammendale Road  
 
Beltsville, MD 20705-1266 
 
Attn: K im Rober tson 
 
  
1 RE: IND 133 602 / A0 005 • DORA 
 
General Corresponden ce: Transfer of IN D Sponsor  
 
  
 
Dear Sir/Madam,  
 
 
 
 
Phase II Multicenter Study of Durvalumab and Olapar ib in Pl atinum t reate d advanced triple nega tive 
breast  cancer – DORA is being conducted under t he above ref erenced I ND. Th is is a prospective, 
randomiz ed, multi- center, s afety and eff icacy study. No s ites have been activated, and no par ticipant s 
have enrolled to the study ye t. Study enr ollment is expected to begin later this year (estima te August  
1st,  2018). The inves tigational plan is to activate a total of 6 s ites (3 US, 2 Korea, 1 Si ngapore) unde r 
this I ND. 
 
   
This is to infor m you that, effective July 02, 2018, I, Dr. Danny Benja min, MD , have t ransferred all 
rights f or IND 133602 to Dr. Sarah Sa mmons, M D of Duke Univ ersity. Dr. Sa mmons w ill recei ve a 
complete record of the IND. 
 
 
 
 
Sincerely,  
 
  
 
Danny 
Benjamin, MD 
PhD 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
7(80)  
  
 
 
2 DANI EL K.  BENJAMIN, MD, MPH, PHD  
 
Kiser-Arena Dis tingui shed Profe ssor of Pediatr ics, 
Duke Univer sity F aculty A ssociate Dir ector, Duk e 
Clinical Res earch I nstitute  
 
300 W. 
Morgan 
Street 
Durham, 
NC 
27701 
 
Ph 919-668-8295 
 
Fax 919-681-9457 
 
Email: danny.benjam i n@duke.edu 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
8(80)  
  
 
  
LIST OF ABBREVIA TIONS AND DEFINITION OF TERMS  
The followi ng abbre viations and special t erms used in the C linical S tudy Protocol. 
(Page left intentionally blank) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
9(80)  
  
 
 
Abbreviation or  
Special term Expl anation  
 
AE adverse eve nt 
 
AESI adverse eve nt of sp ecial int erest 
 
ALP alkaline phosphatase  
 
ALT alanine t rans aminase 
 
APTT activat ed pa rtial thromboplas tin time 
 
AST aspartate t ransaminase 
bid twice daily 
BMI body ma ss index  
 
BP blood pr essure 
 
BUN blood urea nitrogen  
 
CFR Code of Fed eral R egulati ons 
 
CR complete re sponse  
 
CT computeriz ed tomography 
 
CTCAE common terminology crit eria for adver se even ts 
 
DCI Duke Cancer  Institute 
 
DCO data cut-off  
 
DCRI Duke Clinical R esearch  Institute  
 
DNA deoxy-ri bonucleic aci d 
DSB double st rand brea ks 
EC European Commissi on 
ECG Electrocardiogram 
eCRF elect ronic case report form  
 
EOT end of t reatment 
 
ER estrogen r eceptor 
 
FDA Food and D rug Ad ministration 
 
G-CSF granulo cyte colony-st imulati ng factor  
 
GGT gamma glutamy ltransferase 
 
Hb Hemoglobin  
 
Hct Hematocrit  
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
10(80)  
  
 
 
HDPE high densit y polyethylene  
 
HER2 hum an epidermal gr owth f actor r eceptor 2  
 
HIV hum an imm unodeficien cy virus 
HR homologous recombi nation repa ir 
HRD HR de ficiency 
IB investigator’s broch ure 
 
ICF inform ed cons ent form  
 
ICH Internati onal Confe rence on Harmonizati on of T echnical  
Requirements f or Registrati on of Pharma ceuticals f or Hum an Use 
 
IEC Institutional Ethics Commi ttee 
 
Ig Imm unog lobulin 
 
IHC Imm unoh istochemistry 
 
IND investigational new d rug 
 
INR international no rmalized ratio 
 
IP Inve stigational Product  
 
irAEs imm une-relat ed adv erse events  
 
IRB Institutional Review Boar d 
 
iRECIST  RECIST adapt ed for r esponse  with imm unotherap eutics 
 
IV Intravenous  
 
LD longest diameter  
 
LSD lysine-specific hist one demethyla se 
 
MCH mean cell hemoglobin  
 
MCHC mean cell hemoglobi n concentration  
 
MCV mean cell volume  
 
MDS myelodysplastic synd rome 
 
Med DRA medical dictionary f or regulatory activi ties 
 
MRI magnetic resonance imagi ng 
 
mTNBC metastatic triple n egative brea st can cer 
 
NCI National Canc er Inst itute 
 
OAEs other signi ficant adv erse even ts 
od once  daily 
11(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
 OS overall sur vival 
 
PARP poly (adeno sine diphosphate ri bose) polymer ases 
 
PD progre ssive di sease 
 
PD-L1 programm ed de ath ligand-1 
 
PFS progre ssion fr ee survival 
 
PK phar macokineti cs 
PR partial respo nse 
Q2W dose  every 2  weeks 
Q4W dose  every 4  weeks 
RBC red b lood cells 
RECIST  Response  Evalua tion Crit eria i n Solid Tumors  
 
RI reticulocyte In dex 
 
RP2D recomm ended pha se 2 do se 
 
SAE serious adverse ev ent 
 
SD stable di sease 
 
SGGC P Singapo re Guide line for Good C linical P ractice 
 
SSBs single st rand breaks  
 
TILs tumor-in filtrating lymphocytes 
TNBC triple n egative breast cancer 
ULN upper  limit of norm al 
WBC white blood cells  
 
WT Weight  
12(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
PROTOCOL  APP ROVAL PAGE  
 
Phas e II Multice nter Study of Durvalum ab and Olaparib in pla tinum t Reated 
Advanced tripl e negative breast cancer – DORA  
 
 
Protocol Number : ESR-15-11311/EPM 6724 
Protocol Version/ Date: V 6.0, 14Jun2021  
 
Declara tion of Inve stigator  
 
I confirm that I have r ead the above-mentioned protocol and its attachment s. I agree to conduc t 
the des cribed trial in complianc e with all stipula tions of the protocol, regulations and in 
accordance w ith Good Cli nical P ractice (G CP). 
 
I confirm that I have r ead the protocol and its a ttachment s. I agree to conduct the des cribed 
trial in compliance w ith 
 
• This protocol, E SR-15-11311/EPM 6724, 
• Good C linical P ractice guidelines (eg, IC H E6:  Good Clini cal P ractice) , 
• Applicable regulatory re quirements from the United States Code of Federa l 
Regula tions including 21 CFR par ts 312 (Investiga tional New Drug [IND]), 50 
(Prot ection of Human Subj ects), 56 (ins titutional review boar d [IRB]), and 11 
(electronic records and signatures). 
• Country- specific regulatory requirements 
   
 
 
Study Site Principal Investigator Name:                                                                                       
 
 
  
Study Site Principal  Investigator Signature:    
 
   
Date:     
13(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
1    INTRODUC TION  
 
Ten to t wenty percent of invasive breast  tumors are nega tive for all thre e pre dictive and 
prognos tic immunohistoche mical b iomarkers—estrogen r eceptor (ER), progest erone recept or 
and human epidermal growth factor re ceptor 2 (HER2); the se cancers are known collectively as 
triple nega tive breast  cancer (TNBC).1  Women w ith TNBC have an inc reased likelihood of 
distant recurrence and death a s compared w ith women w ith other types of b reast  cancer.2 
 
Breast cancer in the advanced sta ge remains an incura ble dis ease, w ith gene ral goals of therap y 
being to prolong surviva l, palliate symptoms,  and o ptimi ze qua lity of life. In this disease setting, 
continua tion of first- line chemotherapy re sults in a signifi cantly improved overall surviva l 
(OS).3 Whereas maintenance chemotherapy is desi rable to prolong tumor response s, toxic ities 
often limit its continua tion. 
 
The ro le of maintenanc e olapar ib, a poly (adenosine diphosphate ribose) polymera se (PA RP) 
inhibitor, has been explore d in pla tinum-se nsitive relapsed ovar ian cancer; the medi an 
progression-f ree survival (PFS) and OS in subj ects with Breast  Cancer ( BRCA) gene muta tion 
on maintenance olaparib was signifi cantly longer than that in the placebo group, w ith a tole rable 
toxicity profile.4, 5 A signifi cant propor tion of TNBCs arise in BRCA muta tion carriers6, 7 and / 
or have gene expre ssion prof iles (basal- like) similar to that of B RC A-deficient tumo rs.8 The 
therape utic implication  of this lies in exploiting syn thetic lethality, resulting in dis ease control 
with favorable toxicity prof ile similar to that descr ibed in ovar ian cancer. 
 
The immu ne  system can identify tumo r-associated antigens and e liminate the cancerous cells 
expre ssing them; thus it plays an important role in comba ting tumor growth. Howe ver, tum or 
cells w ith reduced immunogenicity or an enhanced immunosuppre ssive m echani sm contribut e 
to the failure of the immune  system in contr olling tumor growth. Several fa ctors ma y contribut e 
to this failure, including expre ssion of immune-inhibitor y molec ules, pre sence o f 
immunosuppre ssive-regulator y T lymphocytes or immunosuppre ssive cytokines w ithin t he 
tumor microenvironment, and down-regula tion of maj or histo compa tibilit y mol ecules and 
tumor anti gens leading to re duced antigen presentation and recogn ition. 
 
The progra mmed dea th ligand-1 (PD-L 1) is part of a comple x system of receptor s and ligands 
that are involved in control of T cell activa tion. In normal tissues, PD-L1 is expre ssed on T cells, 
B cells,  dendr itic cells,  macrophages, and mesenchymal stem cells,  as well in as a var iety of 
non-hematopoie tic cells. The normal func tion of PD-L1 is to regulate the balance between T 
cell activa tion and tolerance. Al so expre ssed by tumor s, PD-L1 ac ts at mu ltiple  sites; thereby, 
tumors evade de tection and e limina tion by the host imm une syst em. In t he tum or 
microenvironment, PD- L1 expre ssed on tumor cells binds to PD-1 on activated T cells re achin g 
the tumo r. This de livers an inhibitory signal to those T cells,  preventing t hem from killing  the 
target tumor cells and th us prot ecting  the tumor from the immune  system. 
 
Rece
nt studies have demonst rated high levels of tumor- infiltrating lymphocytes (TIL s) in 
hormone-re ceptor negative and high g rade tumors such as that of TNBC9,10,11,12 as compar ed 
with hormone- receptor pos itive tumor s. Increased levels of T ILS has been a ssociated w ith 
higher expre ssion of PD-L1 me ssenger ribonucleic acid ( mRNA)13, which is significantly 
14(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
higher in TNBC compared w ith non-TNBC.14 This in turn has been correlated w ith improve d 
prognosis in a number of cancer s, sugges tive of an important anti-tumor i mmune response . An 
anti-PD-L1 anti body could thus be used ther apeuticall y to enhance anti-tumor immune 
responses in subj ects with cancer. In addition, combini ng therapies w ith dis tinct, and potentiall y 
complementary, m echanisms of actions may further enhance t he anti-tumor efficacy of each 
individual t reatm ent. 
 
In the context of advanced TNBC, the combin ation of PARP inhibition and PD-1 immune 
checkpoint inhibition is a therapeutic stra tegy worthy of further inves tigation. 
 
Pr
eclini cal data (unpubli shed) suggests that those triple nega tive cell l ines that are responsi ve 
to pla tinum chemother apy are more likely to respond to t he PARP i nhibitor, olapar ib. W e 
hypothes ize that olapar ib either alone or in combination w ith the PD-L1 inhibit or w ill be 
efficacious in TNBC subjects who have responded to pla tinum-based chem otherapy. 
 
1.1    Drug efficacy, safety and dos ing: background 
 
1.1.1    Olaparib i n the con text of b reast can cer 
 
Olapar ib (AZD2281, KU-0059436) is a potent PARP inhibit or (PARP-1, -2 and -3) that has 
been approved as a monotherap y for tr eating  patients w ith BRCA mutated advanced ov arian 
cancer fo llowing thre e or more prior lines of chem otherapy, it is al so being develope d both as a 
monotherapy (includi ng maintenance) and for combina tion w ith chemoth erapy and other anti- 
cancer agent s. It is approved for use by both the European Commission (EC) and the U.S. Food 
and Drug A dministra tion (FDA) in the trea tment of women w ith BRCA-mutated  advan ced 
ovarian canc er. In January 2018, the FDA granted approval to olap arib tab lets for the trea tment 
of pa tients w ith dele terious or suspected deleterious g ermline  BRCA-mutat ed HER2-nega tive 
metasta tic breast  cancer who have been treated with chemotherap y either in t he neoadjuvant , 
adjuvant or meta static setting. This is based on data from OlympiAD, an open-label randomis ed 
phase III study investigati ng olapar ib vs. physician’s choice of chemothe rapy (capecitabine , 
vinore lbine or  eribulin) in pa tients w ith germline  BRC A mutated, HER2 nega tive meta static 
breast  cancer. 
 
Poly (adenosine diphosphat e ribose) polym erase (PA RP) inhibition is a novel approach that 
targets tumors w ith deficiencies in deoxyribonu cleic acid (DNA) repair m echanism s. PAR P 
enzymes are e ssential for repairin g DNA single-st rand breaks ( SSBs). Inhibiting  PARPs leads 
to the per sistenc e of SSBs, which are then conv erted to the more s erious DNA double-strand 
breaks (DSB s) during the process of DNA re plication. During the pro cess of cell division, DSB s 
can be e fficiently repaired in normal cells by homo logous r ecombina tion repair (HR). Tumors 
with HR def iciencie s (HRD), such as s erous ovarian cancers and B RCA1 and B RCA2  brea st 
cancers15,16,17 cannot accura tely repair the DNA da mage, which may become lethal to cells as i t 
accumulate s. In such tumor type s, olaparib may offer a potentiall y efficacious and le ss toxi c 
cancer trea tment compared wi th currently ava ilable chemotherapy reg imen s. 
 
Olap
arib has been shown to inhibit sel ected tumor cell lines in vitro and in xenog raft and pr imary 
expla nt mode ls, as well as in gene tic BRCA knock-out model s, either as a stand-alone t reatment 
or in combination w ith establish ed chem otherapie s. Cells def icient in homologous 
15(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
recombina tion DNA repair f actor s, notably BRCA1/2, are par ticula rly sens itive to olapar ib 
treatment. 
 
PARP inhibitors such as olapar ib may also enhanc e the DNA-da maging effects of 
chemotherapy.16,18,19 For further informa tion, plea se refer to the current version of the olapar ib 
IB. 
 
1.1.2    Pr eclinical exp erience with olapar ib 
 
Initial in vitro studies have identified olapar ib as an effective agent in potentia ting cell-killing 
by the alkyla ting agent methyl methanesulfonate11. Direct m easurement of PA RP-1 inhibitor y 
activity in SW620 cell lysates identified the IC 50 for PA RP-1 inhibi tion to be around 6 nm, w ith 
total abla tion of PA RP-1 activity to be at concentr ations of 30–100 nM .11 The ability of olaparib 
to potentia te antitumor activity of te mozolomide was further evaluated in vivo in anima ls 
bearing SW620-xenografted tumor s. There was cl ear potentia tion of te mozol omide activity b y 
olapar ib, which was well tol erated when a dminist ered in combination.11 Furthermore, cell lines 
that are def icient in homologous recombina tion as a result of non-func tional B RCA1 or B RCA 2 
have been shown to be profoundly sens itive to PARP inhibi tion.3,12 
 
 
1.1.3    Toxicology and saf ety pharmacology su mmary for olaparib  
 
Olapar ib has been tested in a standar d range of s afety pharmacology s tudie s, eg, do g 
cardiovascula r and respiratory func tion test s, and the rat Irwin test. There were no noticeabl e 
effects on t he cardiovascula r or respiratory pa rameters in the anaesthe tized dog or any 
behaviora l, autonomic, or motor effects in the rats at the doses studied.20 
 
Toxico l ogy s tudies indi cate that the bone m arrow is the t arget organ of toxicity. In toxicity 
studies up to 6 months in rats and dog s, any changes in hematol ogy parameters were fully or 
partially resolved upon w ithdrawal of the drug. Olapar ib was found to have some mutageni c 
effects in rats that were to be expected given its pr imary target. There were no reproduc tive 
adver se effects in male rats, but fetal survival was decr eased and fetal malforma tions increase d, 
again to be expected given the pr im ary phar macology of olapar ib. 
 
Further informa tion ca n be found in the current v ersion of the olap arib Inves tigator’s Brochure 
(IB). 
 
1.1.4     C linical exp erience wit h olaparib  
 
Clini cal exper ience w ith olapar ib is fully des cribed in the cu rrent version of the olap arib 
Inves tigator’s Brochu re. 
 
The capsule formula tion of olapar ib was approved in December 2014 by t he European 
commission (EC) f or the indi cation: monotherapy for the maintenance tr eatment of adul t 
patients w ith platinum-sens itive relapsed B RCA-mutated (g ermline  and/or soma tic) high 
grade serous epithe lial ov arian, fa llopian tube or pr imary per itoneal cancer who are in 
response to pla tinum-based chemotherapy. The United States (US) Food and Dr ug 
Administ ration (FDA ) has approved olap arib capsules as monotherapy in pa tients w ith 
16(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
delet erious or susp ected delet erious g ermline BRCA mutated (as detected by an F DA 
approved test ) advanced ovar ian cancer who have been treated w ith thre e or more prior lines 
of chemotherapy. The tablet formula tion was regist ered for use in the US in 
August 2017 for ovar ian cancer and in January 2018 for brea st cancer. All ongoing studies, 
including the Pha se III reg istration studie s, are being pe rformed w ith the tablet formula tion. 
and the ma jority of pa tients t reated w ith olaparib in A straZeneca-sponsore d clinical studie s 
have re ceived the tablet formula tion. 
 
As of 15 De cember 2018, approx imately 10682 p atients are estimated to have received 
olapar ib in c linical progra mme s, inves tigator spon sored studies and collabora tive group 
studie s. An e stimated 6956 subj ects w ith ovar ian, breast, gastric, pancr eatic, and a v ariety of 
other solid  tumo rs are estimated to have re ceived t reatment w ith olaparib across the dos e range 
10 mg once daily to 600 mg twice daily (bid) in AstraZen eca-sponsore d, investigator- 
sponsore d, and collabor ative group studie s. Olaparib ha s been given a s either monotherapy o r 
in combina tion w ith other chemotherapy/anti-cancer agent s. Since 2012/2013, most ne w 
clinical studies have utilized the tablet formula tion, which was designed to de liver t he 
therapeutic dose of olaparib in fewer dose units than the capsule. Of the 6108 pa tients in 
AstraZeneca-sponsore d, int erventional studies,1567 received the capsule formula tion, 4516 
received the tablet formula tion, and 25 re ceived both capsule and tablet. 
 
The tablet formula tion of olapar ib (2 tablets bid) is considered much more subj ect-friendly ; 
the tablet dose of 300 mg bid has been shown to demonst rate similar effic acy in te rms of 
tumor shrinka ge in BRCA-mutated ovar ian cancer subj ects a s compa red with the 400 mg bid 
capsule formula tion—together w ith an acceptable s afety prof ile. 
 
  
The regula tory approval st atus of the tablet formula tion of olapar ib is as fo llows: 
 
US: App roved in Augu st 2017 for maintenanc e treatment of adult pa tients w ith recurrent 
epithe lial ovar ian, fa llopian tube or pr imary peritoneal cancer foll owing response to pla tinum- 
based chemothe rapy; and for the t reatment of adult pa tients w ith delet erious or suspected 
delet erious g ermline BRCA mutated advanced ov arian cancer who have been t reated w ith 3 or 
more prior lines of chemotherapy. Approved in January 2018 for pa tients w ith delet erious or 
suspected dele terious ger mline B RCA mutated HER2 nega tive metastati c br east  cancer who 
have previously been treated w ith chemothe rapy in the neoadjuvant, adjuvant or metasta tic 
setting.  Pa tients w ith hormone re ceptor positive breast cancer should have been treated w ith a 
prior endocr ine therapy or be considered inappropriate for endocr ine treatment. 
 
EU indication: Approved in May 2018 as monotherapy for the maintenance t reatment of 
adult pa tients w ith platinum-sens itive relapsed high-g rade ep ithelial ovar ian, fallopian tube 
or pr imary per itoneal can cer who are in response (complete or par tial) to pla tinum-bas ed 
chemotherapy. 
 
Japan: Approved in January 2018 as maintenance t reatment for adult pa tients w ith recurre nt 
ovarian cancer who are sens itive to pla tinum based chemotherapy. 
17(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
Emergi ng safety prof ile indi cate that olap arib is generally well tol erated at monotherapy dose s 
up to 400 mg bid (capsule formula tion) and 300 mg bid (tablet formulation) in subj ects w ith 
solid tumor s. Administra tion of olapar ib monotherap y has been a ssociated w ith reports of 
labora tory findings and/or c linical dia gnoses of: 
 
• Hematologi cal toxicity: 
• Ane mia, (very common and of all CTCAE grade s) 
• Neutropenia (common) 
• Lymphopenia (uncommon) 
• Thrombocytopenia (comm on) 
• M ean corpuscular volume eleva tion 
• Increased crea tinine, gen erally mild or moderate intensity (CTCAE Grade 1 or 2) 
• Nausea and vomiting, generally mild or moderate (CTCAE Grade 1 or 2), int ermittent 
and manageable on continued t reatment 
• Stoma titis, generally mild or moderate (CTCAE Grad 1 or 2) 
• Decr eased appe tite, ge nerally mild or moderate intensity (CTCAE Grade 1 or 2) 
• Di arrhea, gen erally mild or moderate  intensity (CTCAE Grade 1 or 2) 
• Dyspepsia and upper abdominal pain, gene rally mild or moderate  intensity (CTCA E 
Grade 1 or 2) 
• Dysgeusia, gene rally mild or moderate intensity (CTCAE Grade 1 or 2) 
• Dy spnea, very common, (CTCAE all grade s) 
• Fatigue (including astheni a), generally mild or m oderate intensity (CTCAE Grade 1 or 
2) 
• Headache, generally mild or moderate intensity (CTCAE Grade 1 or 2) 
• Dizziness, generally mild or moderate intensity (CTCAE Grade 1 or 2) 
• Cough, gen erally mild or moderate intensity (CTCAE Grade 1 or 2 
 
Myelodyspla stic syndro me (MDS) and acute myeloid leuke mia have been reported in <1% of 
subjects. The cases were typi cal of secondary MDS or therapy related acute myeloid leuke mia. 
The dura tion of therapy w ith olapar ib in subjects who developed s econdary MDS  or acute 
myeloid leuke mia varied from <6 months to >2 y ears. All subje cts had potential c ontributing 
factors for the developme nt of  MDS/acute myeloid leuke mia, having received extensi ve 
previous chemothe rapy with pla tinum agent s. Many had al so received other DNA-d amaging 
agent s. 
 
New p
rimary malignancies have been reported in a small number of subject s. There were othe r 
contributing factors or potential alternative explanati ons for the development of the new pr imary 
malignancy in all cases. 
 
Pneumonitis events ha ve been reported in <1% of subj ects receiving olap arib. The reports of 
pneumonitis h ad no consistent c linical pa ttern and were confounded by a number of 
predisposing factors (can cer and/or metastases in lung s, underlying pulmonar y disease , smoki ng 
history, and/or pre vious chemotherapy and ra dioth erapy). 
18(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
1.1.5    C linical exp erience wit h durvalu mab 
 
Durvalumab is an inves tigational human monoclonal antibody of the immunoglobu lin (Ig) G 1 
kappa subcla ss that inhib its bindi ng of PD-L1 to PD-1 and CD80. 
 
As of the Data cut-off (DCO) dates (12 July 2018) , a total of 5127 subj ects have been enrolle d 
and t reated in ongoing durvalumab c linical studie s. Of these, 2229 pa tients re ceived durvalumab 
monotherapy, 1573 pa tients received durvalumab in combina tion w ith tremelimumab, and 1325 
patients re ceived durvalumab in combina tion w ith an inves tigationa l and or an approved 
product. No studies have been completed or t erminated pre matu rely due to toxicity. 
 
Durvalumab has b een given in ongoing studies as monotherap y or in combina tion w ith othe r 
drugs. The majority of safety data is based on the first- in-human single agent study in subj ects 
with advanced so lid tumors ( Study 1108). Durvalumab wa s given int ravenous (IV) every 2 or 
3 weeks in a 3+3 dose es calation followe d by expansion in 8 solid tumor type s, one of whic h 
being TNBC. In the expansion cohort, durvalumab was given at a dose of 10 mg/kg IV every 
2 weeks. Ov erall, the most frequently reported adver se events ( AEs)  were fatigue, naus ea, 
dys pnea, decr eased appetite, cons tipation, di arrhea, vomiting, cough, pyrexia, back pain, a nd 
rash. Approx imately half of the se AEs were Grade 1 to 2 in sever ity and manag eable by gen eral 
treatment guide lines. Grade 3 or higher A Es were noted in 35.9%. The  events occurring in mor e 
than 1% of subje cts w ere dy spnea (5.1%), increased ga mma-glutamy ltransferase (3.3%); 
fatigue, gen eral phys ical health de teriora tion, inc reased a spartate a minot ransferase, and ba ck 
pain (2.3% e ach); anemia and dehyd ration (1.8% each); and abdomina l pain vomiting,  sepsis, 
syncope, and hypotension (1.3% each). No dose-li miting  toxicities have been reported. 
 
Eff
icacy data on durvalumab monotherapy in the expansion cohort was presented at Am erican 
Societ y of Clinical Oncology (A SCO) 2014. W ith a median f ollow-up of 6 weeks, tum or 
shrinka ge has alr eady been seen in multiple tumor type s. Dura ble responses have al so been 
observed; this supports further developme nt of  durvalumab. Clini cal a ssessments and subj ect 
enrollment are ongoing. 
 
1.2    Research hypothesis  
 
Preclinical d ata (unpublished) sugge sts that triple nega tive cell lines that are responsive to 
platinum chemotherapy are more likely to respond to the PARP inhibitor, olapar ib. In t he 
context of advanced TNBC, t he combina tion of PARP inhibition and PD-1 immune checkpoint 
inhibition  is a therape utic strategy worthy of fur ther inves tigation. We hypothes ize that olapar ib 
either alone or in combina tion w ith the PD-L1 inhibitor, durvalumab may be e fficacious in 
TNBC pa tients who have responded to pla tinum-based therapy. 
 
1.3    Rationale for conduct ing th is study 
 
Women w ith TNBC do not respond to estrogen/proges terone based endocrine therapy or othe r 
available targeted agents.  Che moth erapy remains the mainstay of trea tment. In the meta static 
setting, these tumo rs are a ssociated w ith a shor ter median time to relapse and death compared 
to other metasta tic br east cancer subtype s.21  With the poore st prognosis of all br east cancer 
subtype s, this dis ease represents an important challenge and remains an unmet c linical need. 
19(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
Over the la st 5 ye ars, potential t argeted strategies for mol ecula r sub types of TNBC have bee n 
identified. A signif icant propor tion of TNBCs (~30%) arises in BRCA gene mutation ca rriers 
or have gene expre ssion prof iles s imilar to B RCA def icient tumors representing a  defective 
DNA da mage repair system.22,23 The therapeutic i mplication  of this susceptibility has led to the 
development of synthe tic lethality strategies such as trea tment w ith poly ADP-ribose 
polymerases (PA RP) inhibitors such as olapar ib.   Further more , patholog ical studies h ave 
reported pre dictive and prognos tic role s for the presence of TILs in hormone receptor nega tive 
and high-g rade tumors such as advanced TNBC.24,25  Cons istent w ith these finding s, multiple 
transcriptomic stud ies have identified TNBC subtypes cha racterized by alt ered expre ssion of 
immun e-response gene s.23 Several hypotheses for per sistent dis ease despite chemotherapy and 
an active immune sys tem response have b een proposed, includi ng masking of malignant ce lls 
by a variety of m echanism s, chronic anti gen exposure , and “T cell exhaustion”. A s eries of ne w 
immun e-based the rapies in which disruption of ma lignant cell ma sking by inhibition of CTLA- 
4 or PD-1 /PD-L1 axes have entered t he clinic. These have been studied in the context of several 
Phase 1 studie s, which have reported signif icant promising c linical activity.26,27,28 This clinical 
protocol a ssesses the activity of olapar ib as well as the combina tion of  olapar ib and PD- L1 
immunotherapy where t wo therapies w ith distin ct and potentially complementary m echanisms 
of actions may further enhance anti-tumor efficacy. 
 
1.4    Benefit/ri sk and et hical asse ssme nt 
 
Data from the ava ilable pre -clinical studies and subsequent c linical developme nt progra m 
demonst rate that olapar ib appe ars to be ac tive and gen erally well tolerated in subj ects w ith solid 
tumor s, includi ng those w ith BRCA -mutated cancers. In ov arian cancer, responses have b een 
seen in all subj ect groups, includi ng platinum- resistant and refractory cancer. 
 
From ava ilable studie s, ther e is no evidenc e of any unexpected toxicity following long-t erm 
olapar ib (capsule) monotherapy exposure in subje cts w ith advanced cancer. 
 
Adver se labora tory findings and/or c linical d iagnoses considered to be a ssociated w ith 
administra tion of olapar ib monotherapy include hematolog ical ef fects (ane mia, neutropenia, 
lymphopenia, thrombocytopenia, MCV eleva tion and incr ease in blood creatinine) , nausea a nd 
vomiting, decr eased app etite, di arrhea, dy spepsia, stoma titis, upper abdominal pain, dysgeusi a, 
fatigue (includi ng astheni a), headache, dyspnea and diz ziness. Most of these events were 
generally mild or modera te in intensity. 
 
In a small number of subjects, pneumonitis, M DS/AML, and new pr imary malignancies ha ve 
been obs erved. Evidence from across the development prog ram for olap arib does not support a 
conclusion that there is a causal rela tionshi p between olap arib and the se event s. These are 
important potential risks for olapar ib and are being kept under close ph armacosurve illance. 
 
Identified risks w ith durvalumab are diarrhea, increases in t ransaminases, pneumonitis and 
colitis.  
 
Potential risks include endocr inopathies (hypo- and hyp er-thyroidism, hypophys itis and ad renal 
insufficiency),    development    of    ty pe    1    diabete s    me llitus,    hepa titis/h epatotoxicity, 
20(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
neurotoxic ities, nephr itis, pancr eatitis, der matitis, infusion- related reac tions, anaphylaxi s, 
hypersens itivity or allergic r eactions, and immune complex dis ease. Further informa tion on 
these risks can be found in the current ver sion of the durvalumab IB. 
 
1.5    Rationale for drug dosing in th is study 
 
1.5.1    Rationale for dose of olaparib  
 
As of 15 December 2018, approx imately 10682 patients are estimated to have received olaparib 
in clinical prog ramme s, inves tigator sponsore d studies and collabora tive group studie s. An 
estimated 6956 subj ects with ovar ian, br east, gastric, pancr eatic, and a variet y of other solid 
tumors are estimated to have received t reatm ent with olapar ib across the dose ra nge 10 mg onc e 
daily to  600 mg  twice  daily (bid)  in  A straZen eca-sponso red, inves tigator-sponsore d, and 
collabora tive group studie s. The r ecomm ended monotherapy table t dose of olapar ib is 300 m g 
b
id.  Olapar ib  is  generally  well  tolerated  a t  monotherap y  dose s  of  300 mg  bid  (table t 
formula tion) in subj ects w ith solid  tumors. Toxicities such as hematological, ga strointe stinal, 
eg, naus ea, vomiting  and di arrhea, anore xia, dysgeusia, fatigues, etc., are generally Gra de 1 or 
Grade 2. 
 
This study w ill use olaparib at the recomm ended monotherapy tablet dose of  300 mg bid. 
 
1.5.2    Rationale for Durvalumab fixe d dos ing 
 
A popula tion PK model was developed for durval umab using monotherapy  data from a Pha se 
1 stu dy ( study 1108;  N=292; dose s= 0.1 to 10 mg/kg Q2W or 15 mg/kg Q3W; solid tumors ). 
Popula tion PK analysis indi cated only minor impac t of body weight (W T) on PK of durvaluma b 
(coefficient of ≤ 0.5). The impact of bod y WT-based (10 mg/ kg Q2W) and fixed dosing (750 
mg Q2W) of durvalumab was evaluated by comparing p redicted s teady state PK concent rations 
(5th, median and 95th percentile s) using the popula tion PK model. A fixe d dose  of 750 m g was 
selected to approx imate 10 mg/kg (based on median body WT of ~75 kg).  A total of 1000 
patients were simulated using body WT distribution of  40–120 kg. Simula tion results 
demonst rate that body WT-based and fixed dosing reg imens yie ld similar median steady state 
PK concent rations w ith slightly less overa ll be tween-subje ct var iabilit y with fixed dosi ng 
regimen. 
 
Similar findings have been reported by other s.29,30,31,32,33 Wang and colleagues inves tigated 12 
monoclonal antibodies and found that fixed- and body s ize-based dosi ng perform s imilar ly, w ith 
fixed dos ing being be tter for 7 of 12 antibodie s.30. In add ition, they inves tigated 18 therapeutic 
proteins and pepti des and showe d that fixed dosing pe rformed be tter for 12 of 18 in t erms of 
reducing the betw een-subject var iability in ph armacokine tic/phar macodyna mics paramet ers.31 
 
A fixed dosing approach is preferre d by the pres cribing comm unity due to ease of use and 
reduced dosing error s. Given expecta tion of  similar phar macokine tic exposure and var iability , 
we considered it feasible to sw itch to fixed dosi ng regimens. Based on avera ge body WT of 75 
kg, a fixed dose of 1500 mg Q4W durvalumab (equivalent to 20 mg /kg Q4W) is included in t he 
curre nt study. Fixed dosing of durvalumab is recommended only for subject s with > 30kg body 
21(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
weight due to endotoxin exposure .  Patients with a body weight le ss than or equal to 30 k g 
should be dosed using a weight-based dosing schedule (Appendix D). 
 
  
1.5.3 Rationale for dose of olaparib i n combination wit h durvalu mab 
 
A recent pha se 1 study presented re sults for durvalumab therapy in combin ation w ith 
olapar ib for ov arian cancer and TNBC, at the Am erican Society of Clini cal Oncology (A SCO) 
2016. 10 ovar ian cancer and 2 TNBC pa tients were included. Grade 3/4 adver se event s 
included lymphopenia (2/12) and ane mia (1/12).  1 PR (6 months) and 5 S D ≥ 4 months w ere 
seen in 9 evaluable pa tients, yieldi ng a 67% dis ease control rate (DCR).33 
 
Dosage of olap arib tablet s 300 mg bid along w ith durvalumab 1500 mg Q4W was tol erated 
and eff icacious in the se patients who did not posse ss ger mline  BRCA mutations, and is t he 
recommended pha se 2 do se (RP2D) employed in this study. 33 
22(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
 
2    STUDY OBJECTIVES  
 
2.1    Primary obje ctive 
 
To determine the e fficacy as asse ssed by PFS (based on RECIST 1.1) of maintenance olapar ib 
or olapar ib in combina tion w ith durvalumab f ollowing c linical ben efit (comple te response [ CR], 
partial re sponse [ PR] or stable dis ease [SD]) w ith pla tinum based chemothe rapy in the 1st or 2nd 
line setting for tr eatment of meta static triple nega tive breast cancer ( mTNBC). 
 
2.2     S econdary ob jectives 
 
• To d etermine  the  efficacy  of  maintenanc e  olapar ib  followin g  platinum  base d 
chemotherapy a s assessed by ove rall survival (OS). 
 
• To determine the efficacy of maintenance olaparib in combina tion with durvaluma b 
following pla tinum based chemotherapy as a ssessed by ove rall survival (OS). 
 
• To determine the sa fety and tol erability of maintenance olap arib. 
 
• To determine the safety and tol erability of maintenance olapar ib in comb ination with 
durvalumab. 
 
• To  d etermine the   e fficacy  of   maintenanc e  olapar ib  followin g  platinum-bas ed 
chemotherapy a s assessed by ove rall response rate (ORR) based on RECIST 1.1. 
 
• To determine the efficacy of maintenance olaparib in combina tion w ith durvalumab 
following pla tinum-based chemotherapy as asse ssed by overall response rate (ORR) 
based on RECIST 1.1. 
 
• To  d etermine the   e fficacy  of   maintenanc e  olapar ib  followin g  platinum-bas ed 
chemotherapy a s assessed by c linical benef it rate (CBR) based on RECIST 1.1. 
 
• To determine the efficacy of maintenance olaparib in combina tion w ith durvaluma b 
following pla tinum-based chemotherap y as assessed by c linical benef it rate (CBR ) based 
on RECIST 1.1. 
 
 
 
 
2.3    Expl oratory ob jectives 
 
• To char acterize the mol ecular epide miology of biom arkers in TNBC through whol e 
exome sequencing and immunohistoche mistry studie s. 
 
• To explore the immune microenvironment of TNBC including, but not limited to, tumor- 
infiltrating lymphocytes (TILs), macrophages and other s. 
23(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
• To explore the tumor immunosuppre ssive microenvironment including but not limite d 
to progra mmed death- ligand- 1 status on tum or and a ssociated tissues. 
 
• To analyze epigene tic changes in TNBC includi ng, but not limited to, DN A methylation 
and non-coding R NAs such as miR NAs.  
 
• To validate the role of minimally invasive blood-based markers such as ci rculating 
tumor cells or pla sma DNA 
 
• To perf orm muta tional analysis on normal g ermline DNA obtained from blood sample s 
and buccal s wabs. 
 
• Through sy stematic acqu isition  of tumor  biopsie s, additional tissue  will be banked in 
the Duke Pathology central biore pository for future gene tic resea rch; it repre sents an 
invaluable resource tow ard achieving a deeper under standin g of the m echani sm of 
resistance or re sponse to olapar ib and or durvalumab. 
 
• To compare pa tients randomiz ed to olapar ib and olapar ib in combination w ith the 
durvalumab arm on their eff icacy outcome measures. 
 
• To  determine  t he  efficacy  as  asse ssed  b y  PFS,  ORR,  dura tion  of  response  of 
maintenance olap arib in combina tion w ith durvalumab based on iR ECIST criteria 
24(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
 
Durvalumab 
Durvalumab 
R A N D O M I Z E D  
 
 
 
3    STUDY DESI GN 
 
3.1    Overall st udy s tructure and flow chart  
 
This is a randomiz ed, int ernational, multicent er, Pha se II study designed to explore the eff icacy 
of olapar ib or olap arib in combina tion w ith durvalumab in pla tinum-treated mTNBC (S ee 
Figure 1). The pr imary obj ectives are to explore olaparib or olaparib in combina tion w ith 
durvalumab as maintenance therapy following clini cal benef it with platinum-based the rapy in 
subjects w ith mTNBC. 
 
Figure 1: St udy Sch ema 
 
 
 
 
Manda tory blood and tissue 
banki ng (archival tissue  or 
fresh tissue  biopsy) 1° Endpoint  = PFS 
2° Endpoin t = OS, toxicity , ORR 
Exploratory = b iomarker analyses 
 
 
Eligibil ity: 
Advanced / Met TNBC 
 
 
Non PD on platinu m 
chemo (1L/2L) Olapa rib 300mg bid daily Till PD 
 
Olapa rib 300mg bid daily 
 
 
Till PD 
 
   
Durv alum ab 1500mg q4 weeks  
CT q8 w eeks 
 
 
Approx imately 60 subject s with mTNBC who are receiving pla tinum-based chemotherapy and 
who have had no more than 2 lines of chemother apy in the metasta tic or advanced se tting, w ith 
one of those bei ng a platinum, w ill be enrolled. Subj ects w ill be e ligible for this study following a 
minimum of thre e 3-weekly cycles or six 1- weekly doses of pla tinum-based (cisplatin or 
carbopla tin) chemothe rapy as single agent or combina tion therapy as p rescribed by their treating 
physician.  Subj ects can continue w ith further cycles of chemotherapy or be rando mized an y 
time after e ligibilit y to allow for s creening procedure s to proc eed without int erruption of 
ongoing trea tment. Subj ects der iving c linical benef it (CR / PR / SD) w ith platinum-bas ed 
therap y as det ermined by t he treating physician w ill be e ligible and randomized in a 1:1 ratio 
stratified by site and by the line of chemotherapy ( in the meta static setting). Randomiz ation wil l 
be used to a llocate subje cts to e ither the olapar ib or olapar ib in combina tion w ith durvalumab 
arm, and compar isons bet ween treatment reg imens are planned  as an explo ratory obj ective. The 
purpose of randomiz ation was to re duce bias d ue to  subj ect sel ection  into either treatment arm. 
25(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
Germline  BRCA muta tion testing  is not mandated for entr y onto the trial; howe ver, previous 
BRCA te st data will be collected to asc ertain the number of known B RCA muta tion carriers -- 
which w ill be limited to 10 in tota l. 
 
Tumor status w ill be evaluated as per RECIST v1.1 criteria. Tumor m easurement for dis ease 
evalua tion w ill be perf ormed every 8 weeks on both arms, regardle ss of initial response t o 
platinum chemotherapy. Estima tion of  PFS, dura tion of response and tumor response w ill be 
based on RECIST v1.1. 
 
Followi ng randomiz ation, subj ects w ill discontinue pla tinum chemotherapy and receive e ither 
olapar ib tablets or olap arib in combina tion w ith durvalumab. Study t reatment should commenc e 
following re solution of  chemoth erapy toxicities to CTCAE g rade 2 or le ss and no more than 4 
weeks after la st dose of chemotherapy. S tudy tr eatment w ill continue until dis ease progre ssion, 
intolerable to xicity, el ective withdrawal fr om the study, or study completi on or  termina tion. 
Upon t reatment discontinua tion, subj ects w ill be followe d every 2 months f or survival. 
 
Safety w ill be evaluated on an ongoing basis in this study through t he monitoring of all s erious 
and non-serious adv erse event s, graded accordi ng to  National Can cer I nstitute  Common 
Terminology Cr iteria for Adver se Event s, Version 4.03 (NCI CTCAEv4.03).  
 
3.2    Rationale for st udy design, doses and con trol groups  
 
Subjects suitable for enro llment into  this trial are adult subj ects w ith histol ogically document ed 
triple nega tive adenocar cinoma of the br east that is inoperable, lo cally advanced, or meta static, 
and is not amenabl e to res ection w ith cu rative intent, and who have received pla tinum-bas ed 
chemotherapy in the 1st or 2nd line setting. 
 
Rando
mization w ill be used to a llocate subj ects to either the olaparib or olap arib in combina tion 
with durvalumab arm, and compar isons bet ween t reatment reg imens are planne d. The purpos e 
of randomiz ation is to re duce bias due to subje ct sel ection  into either trea tment arm. 
 
3.3    Rationale for prior treat ment wit h platinum  
 
The standar d of care chemoth erapeutic agent for unsel ected and advanced TNBC include taxa ne 
chemotherapy . A growing body of pr eclinical and c linical da ta sugge sts that platinum 
chemotherapy has a role to pla y in the trea tment of both early and advance d TNBC, based on 
the hypothe sis of gr eater sus ceptibility of TNBC to DNA-da maging chemotherapy agents. 
Clinical activi ty of the platinum c ombin ation (gemc itabine / cispla tin) has pre viously been 
evaluated w ith a response rate of around 30%34. The TNT trial evaluated 6 cycles of pla tinum 
therapy w ith monotherapy c arbopla tin dosed at area under the curve (AUC) 6 every 3 w eekly 
in compar ison to 6 cy cles of taxane therapy w ith docetaxel dosed at 100mg /m2 every 3 weeks 
with the option of crossover upon trea tment progre ssion or toxicit y in pa tients who had not 
previously r eceived t reatment for advanced TN BC. In the overall population, ther e was no 
difference bet ween the ORR to carbopla tin and to docetaxel 31.4% ver sus 34.0% (absolut e 
difference -2.6%, 95% CI -12.1 to 6.9; p=0.66). There was no diff erence in median PFS 3.1 
months (95% CI 2.4-4.2) v ersus 4.4 months (95% CI 4.1-5.1) or OS, 12.8 months (95% CI 10.6- 
15.3) v ersus 12.0 months (95% CI, 10.2-13.0) in both t reatment groups. Pa tients w ith a 
26(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
delet erious muta tion in B RCA1/2 genes had a signifi cantly be tter ORR to carbopla tin tha n 
docetaxe l (ORR 68% v ersus 33.3%; p=0.03). PFS was also longer 6.8 months ver sus 4.4 
months; p=0.002. No dif ference was obs erved based on response to crossover trea tment w ith 
the a lternative drug. Thus  platinum chemothera py represents a widely used and appropriat e 
therapy for subj ects in the fir st / second line setting35. 
 
3.4    Inc lusion Cr iteria 
 
Subjects must m eet all of the below criteria to be e ligible for randomiz ation and study trea tment. 
 
 
1.   Age ≥ 21 years of age 
 
2.   ECOG perf ormance status 0-2 
 
3.   Inoperable locally a dvanced or metasta tic br east cancer not amenable to resection  with 
curative intent and histolo gically confirmed to be estrogen receptor (ER) nega tive, 
progest erone re ceptor (PR) nega tive, and HER2 nega tive: 
 
• ER nega tive status is def ined as < 1% tumor cells positive for ER by 
immunohisto chemistry (IHC), irrespective of st aining intensity 
• PR nega tive status is def ined as < 1% tumor cells positive  for PR by IHC, 
irrespective  of st aining intensity 
• NOTE:  Enrollment is permitted for ER/PR low-expre ssion subj ects (def ined as ≤ 
 
10 %) who are expected to benef it from this trial at the inves tigator’s discr etion. 
 
• HER2 nega tive status is det ermined by: 
 
• IHC 1+, as def ined by incomplete membra ne staining tha t 
is faint/barely perceptible  and w ithin > 10% of invasi ve 
tumor cells,  or 
• IHC 0, as def ined by no staining obs erved or mem brane 
staining th at is incomple te and is faint/barely perce ptible 
and w ithin ≤ 10%  of the invasive tumor cells,  or 
• FISH negative based on: 
 
• Single-probe average HER2 copy number 
 
< 4.0 signals / cell, or 
 
• Dual-probe HER2/C EP17 ratio < 2.0 w ith 
an avera ge HER2 copy numbe r < 4.0 
signals / cell  
27(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
4.  Minimum six 1- weekly doses or thre e 3-w eekly doses of platinum che moth erapy 
(monotherap y or combina tion therapy at inves tigator’s dis cretion) w ith stable dis ease 
(SD), par tial response ( PR) or complet e respon se (CR) to the pla tinum therapy as 
assessed by investigator. 
5.   Has received no more than 2 pri or chemotherapy lines for metasta tic breast  canc er 
includi ng current pla tinum-based chemotherapy. 
6.   Able to provide a representa tive forma lin-fixed, paraff in embedded tumor specime n 
archival or fresh tissue  for correla tive studies and biom arker analysi s. 
7.   Hemoglobin ≥ 9.0 g/dL and no blood t ransfusions in t he 28 days prior to study entry. 
 
Absolute neutrophil count ≥1,500/mm3. Platelet count ≥100 x  10^9/L. 
 
 
8.   Tot al bilirubin <1.5 x the upper limit of normal (ULN) w ith the f ollowing ex ception: 
subjects w ith known G ilbert's dis ease who have s erum bilirubin <3 x ULN may be 
enrolled. 
 
9.   A spartate t ransaminase (AS T) and alanine t ransaminase (ALT) <2.5 x ULN w ith the 
following ex ceptions: subjects w ith documented liver or bone metastases may have AS T 
and ALT <5 x ULN. 
 
10. Alk
aline phosphata se (ALP) <2 x ULN (<5 x ULN in subj ects w ith known liver 
involvement and <7 U LN in subj ects w ith know n bone involvement). 
 
11. S erum creatinine  <1.5 x ULN or cr eatini ne clearance >51 mL /min by the Cockcr oft- 
Gault formul a (Cockcrof t and Gault 1976) or by 24-hour urine co llection f or 
determina tion of cr eatinine clea rance. 
 
12. For subj ects of childb earing poten tial, agr eement (by both subj ect and partner ) to use 
two effective forms of cont raception, includi ng surg ical sterilization, reliable barr ier 
method, birth control pills,  cont raceptive h ormone implant s, or tr ue abstinence and t o 
continue its use for the dura tion of the study and for 3 months after la st dose of stud y 
treatment. 
 
13. Subj ects of childbe aring potenti al should have a nega tive urine or s erum pregnancy te st 
during their screenin g visit. If the uri ne test is pos itive or cannot be confirmed a s 
negative, a serum pregnancy te st will be required. 
28(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
14. Subj ects w illing  and able to comply w ith the protocol for the dura tion of the stud y 
includi ng undergoing trea tment and scheduled vis its and exa mina tion. 
 
15. For inclusion in gene tic research, subje cts m ust provide informed consent for gene tic 
research colle ction of specimens to be store d at repos itory f or future research. 
 
3.5 Exc lusion Criteria 
 
Subjects should not enter the study if any of the fo llowing exclusion criteria are fulf illed. 
 
1. Curre ntly p articipa ting and receivi ng study the rapy or has par ticipated in a study of a n 
inves tigational agent and received study the rapy or used an inves tigation device w ithin 
4 w eeks of fir st dose of tr eatment. Subj ects who have entered t he follow- up phase of an 
investigational study may par ticipate as long as it has been 4 weeks since la st dose of 
the pre vious inves tigational agent of devi ce. 
 
2. Concurre nt  enr ollme nt  in  anothe r  clinical  study,  unle ss  it  is  an  obs ervational 
(non-int erventiona l) clinical study or the f ollow-up per iod of an int erventional study. 
 
3. Active autoimmune  disea se that has required systemic treatment in past 2 ye ars (ie, w ith 
use of dis ease modifying agent s, cor ticos teroids or immunosuppre ssive d rugs). 
Repl acement therapy (eg, thyroxine, insulin, or physiologic cor ticos teroid replaceme nt 
therapy for ad renal or pit uitary insufficiency, or similar t reatm ent) is not considered a 
form of sy stemic treatment. 
 
4.
 Is taking chronic syste mic steroids in doses > 10mg of prednisolone or equivalent w ithin 
7 days prior to the fir st dose of trial trea tment. 
 
5. P revious t reatment w ith PARP inhibi tors including olap arib. 
 
6. Patients that have required discontinuation of treatment due to treatment -related toxicities 
from prior therapy with PD -1, PDL -1 or CTLA -4 inhibitors or previous history of 
immune -related grade 3 or 4 adverse event.   
 
7. Known active  central ner vous sy stem meta stasis and / or carcinomatous mening itis. 
Subjects w ith pre viously t reated bra in meta stases may p articipate, provided they have: 
 
a. Stable bra in metastases [w ithout evidence of prog ression by imaging (confirmed b y 
comput erized tomog raphy {C T} scan if CT used at prior imaging) for at l east four 
weeks prior to the fir st dose of trial trea tment**, 
 
b. No evidence of new or enl arging b rain metastase s; any neurologic symptoms shoul d 
have returned to base line, 
 
c. Not used s teroids for br ain metastases in the 7 days prior to trial initiation. Taking 
chronic sy stemic steroids in dose s ≤ 10mg  of prednisolone is a llowed. 
29(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
**This ex ception does not include carcinomatous mening itis, as  subj ects w ith 
carcinomatous me ningitis are excluded reg ardless of c linical stability. 
 
8. History and/or confir med pne umonitis,  or exte nsive bilat eral lung disea se on hi gh 
resolution/spi ral CT s can. 
 
9. Pa tients w ith  suspected  or  confirmed  myel odyspla stic  syndrome/acut e  myeloid 
leuke mia. 
 
10. History of another pr imary malignancy ex cept for: 
 
a.   Ma lignancy treated w ith cura tive intent and with no known active  disea se ≥5 year s 
before the fir st dose of study dru g and of low pote ntial ri sk for recu rrence. 
 
b.   Adequately t reated non-melanoma skin cancer or lentigo ma ligna without evidence o f 
disease. 
 
c.   Adequately tr eated carcinoma in s itu w ithout evidence of dis ease eg, c ervical cancer in 
situ. 
 
11. Major surgery w ithin 2 weeks of starting the study, and subje cts must have recov ered 
from any effects of any major surgery. 
 
12. R eceipt of radiation therapy w ithin 4 weeks pri or to st arting study drug(s). L imited fie ld 
of radiation for pa lliation within  2 weeks of the fir st dose of  study trea tment is allowed 
provided: 
 
a.   The lung is not in  the radiation field 
 
b.   Ir rad
iated lesion( s) cannot be used as target lesions 
 
13. Un controlled  int ercur rent  illness  including,  but  not  limited  to,  ongoi ng  or  ac tive 
infection, symptoma tic conges tive h eart failure, uncontrolled hyper tension, unsta ble 
angina pectori s, cardiac arrhythmia, active peptic ul cer dis ease, active bleedin g diatheses 
includi ng any subj ects known to have evidenc e of acute or chronic hepa titis B, hepa titis 
C or human immunodef iciency virus (HIV), or psychiatric illne ss / social situ ations that 
would limit c omplianc e with study requirements or compr omise the a bility of the subje ct 
to give written informed consen t. 
 
14.
 Subj ects  una ble  to  s wallow  orally  administered  medi cation,  and  subj ects  with 
gastrointe stinal disorder s likely to interfere with absorption of the study me dication. 
 
15. Subj ects requiring t reatment w ith potent inhibitors or inducer s of CYP3A4. 
 
16. P regnant or breast-f eeding women. If br eastf eeding can be stopped prior to stud y 
enrollment until 1 month after the la st study dos e, then the pa tient could be a llowed to 
enter t he study. 
30(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
17. I mmunodeficient subj ects, eg, subj ects who are known to be s erologi cally pos itive f or 
human immunodef iciency virus (HIV). 
 
18. R eceived a live vaccine w ithin 30 days of planned st art of study the rapy. 
 
19. Subj ects w ith a known hyper sensitivity to ola parib or durvalumab, or any of t he 
excipients of the product. 
 
20. Active or prior documented inflammatory bowel disease (eg, Crohn’s dis ease, ul cerative 
colitis)  
 
21. History of a llogeneic organ t ransplant 
 
22. Active bl eeding diatheses 
 
23.
 Pa tients w ith known active hepa tic disea se (ie, Hepa titis B or C) 
 
24. Known history of pre vious c linical diagnosis of tuberculosi s. 
 
For pro cedures for w ithdra wal of incorr ectly enrolled subj ects, see S ection 5.3. 
 
3.6 Restrictions during the st udy 
 
The following restrictions apply w hile the pa tient is  receiving study treatment and for the 
specified times bef ore and after: 
 
 
3.6.1 Pregnancy/B reastf eedin g 
 
1. Female  subje cts  of  childbear ing  poten tial  who  are  sexuall y  active  with  a 
non-sterilized ma le partner must use t wo highl y effective methods of contr aception 
(Table 1) from the time of s creenin g and m ust agree to continue u sing such 
precautions for at l east 1 month after the la st dose of olapar ib or at l east 3 months 
after the last dose of durvalumab.  Male par tners of a female sub ject must use mal e 
condom plus spermicide throughout this per iod. Ce ssation of birth control after thi s 
point should be discussed w ith a responsible physician. 
 
2. Total sexual abs tinence or engaging in sexual ac tivity f or the total dura tion of the tria l 
and the drug washout period (1 month after the la st dose) is an ac ceptable pr actice ; 
howe ver, occasional abstinence, the rhythm method, and the w ithdrawal method are 
not acceptabl e methods of contra ception. Female pa tients should refrain from 
breastfeeding throughout this per iod. 
 
3. Non-sterilized ma le subjects who  are sexually active w ith  a  female p artner o f 
childbear ing potential must  use male condom plus sp ermicide from s creening throug h 
at least 1 month after the la st dose of  olapar ib or at l east 3 months after the last dose 
of durvalumab. Not engaging in sexual ac tivity for the total dura tion of the trial and 
the drug washout period (1 month after the last dose of olapar ib or 3 months after the 
31(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
last dose of durvalumab) is an acceptabl e practice; howe ver, occasional abs tinence, 
the rhythm method, and the w ithdra wal method are not a cceptabl e methods of 
contraception. M ale patients should refrain from sperm dona tion throughout thi s 
period. Female partner s of a male subj ect must use a highly effective  method of 
contraception throughout this per iod. 
 
4. Females of childbear ing potentia l are def ined as those who are not surgically sterile 
(i.e., bilat eral tubal ligation, bilat eral oophorectomy, or complet e hysterectomy) or 
postmenopausal (defined as 12 months w ith no menses w ithout an a lternative medi cal 
cause). 
 
5. Highly ef fective methods  of  cont raception are  described in  Table 1.  A  highl y 
effective method of cont raception is def ined as one that results in a low fai lure rat e 
(ie, le ss than 1% per ye ar) when used consistently and correctly. Note that some 
contraception m ethods are not conside red highly effective (eg, male or female 
condom w ith or w ithout spermicide ; female cap, diaphrag m, or sponge w ith or 
without spermicide; non-copper containing intraut erine device; progestogen-onl y oral 
hormonal contr aceptive p ills wher e inhibition of ovula tion is not the pr imary mode 
of action [excluding Ceraze tte/desogest rel, which is considered highl y effective]; a nd 
triphasic combined ora l contra ceptive pills). 
 
T
able 1: Hig hly Effectivea Methods of Con traception  
 
Barrier/ Intrauterine  Methods Hormonal Methods 
• Copper T intrauterine device 
• Levon orgestr el-releasing intrau terine 
system (eg, Mirena®)b • “Implants”: Etonogestrel-releasing 
implants: eg, Imp lanon® or Norplant® 
• “ Intravaginal Devices”: 
Ethinylestradio l/etonogestrel-r eleasin g 
intravagin al devices: eg,NuvaRing® 
• “Inj ection”: Medrox yprogeste rone 
injection: eg, Depo-P rovera® 
• “Combin ed Pill”: N ormal and low dose 
combin ed oral contr aceptive pill 
• “P atch”: 
Norelgestromin /ethiny lestradiol- 
releasing transderm al system: eg, Orth o 
Evra® 
• “Minip ill”: Progesterone based oral 
contr aceptive p ill using desogestr el: 
eg, Cer azette® 
a Highly eff ective (ie, failure r ate of <1% p er year) 
b This is also co nsidered a hormon al method 
c Cerazette® is currently the only highly eff ective proges terone-bas ed pill 
 
  
 
Contraception  
32(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
Subjects with child-bear ing potential and their partner s, who are sexually ac tive, must ag ree to 
the use of two highly e ffective forms of contr aception throughout their par ticipation in the stud y 
and for 3 months after last dose of study drug(s). 
 
• Condom w ith sp ermicide 
 
and one of the following: 
 
• Oral contr aceptive or ho rmonal therapy (eg, hormone implant s) 
 
• Placement of an intra-u terine devi ce 
 
Acceptable non-hormonal birth control methods include: 
 
Total sexual abs tinence. Abs tinence m ust be  prior to study enrollment, for the total dura tion of 
the study, and one month after la st dose. Vasectomiz ed sexual par tner plus ma le 
condom, w ith par ticipant a ssurance that par tner r eceived post-vas ectom y 
confirma tion of azoosper mia 
 
•           Tubal occlusi on plus male condom w ith sp ermicide 
 
• Intraut erine Device (IUD) plus male condom+ spermicide, provided coils are copper- 
banded 
 
Acceptable hormonal methods: 
 
** The e fficacy of hormonal contra ceptives ma y be reduced if co-ad minis tered w ith olaparib.** 
 
•           Etonogestrel implants (eg, Implanon, Norplan) +male condom w ith sp ermicide 
 
•           Normal and l ow dose combined ora l pills+male condom w ith sp ermicide 
 
•           Nore lgestromin/ethinyl e stradiol t ransder mal sy stem+ma le condom w ith spermicide 
 
• Intravagina l  devic e+mal e  condom  w ith  spermicide  (eg,  ethiny l  estradiol  and 
etonogest rel) 
 
• C eraze tte (desoge strel)+male condom w ith spermicide. C eraze tte is curre ntly th e 
only highly efficacious progest erone-based pill. 
 
3.6.2    Su
rgery  
 
Olapar ib treatme nt should be stopped at l east 3 days prior to planned surgery. After surgery 
olapar ib can be rest arted when the wound has healed. No stoppa ge of  olaparib is required fo r 
any n eedle biopsy pro cedure.  
33(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
3.6.3    Radi ation  
 
Palliative ra diotherapy may be used for t he treatment of pain at the site of bony metastases that 
were pre sent at base line, provided the Investigat or is not of the opinion that the se are indic ative 
of clinical dis ease progre ssion duri ng the study period. Full deta ils of a ll these treatments ar e 
recorded in the subje ct’s notes and appropriate se ction of the e CRF. Study t reatment should be 
discontinued for a minim um of 3 days b efore the subj ect undergoes pa lliative radiation 
treatment. S tudy trea tment should be rest arted w ithin 4 weeks as lo ng as any bone marr ow 
toxicity ha s recove red. 
 
3.6.4    Adm inistration of other anti-can cer agents  
 
Subjects must not receive any other concur rent anti- cance r therapy, incl uding inves tigationa l 
agent s, while on study tr eatment. Subj ects may continue the use of bisphosphonates for bon e 
disease and cor ticost eroids for the symptoma tic control of brain metastase s, provided the dose 
is stable in the la st 7 days and does not ex ceed 10mg of predni solone or equivalent. 
 
.Full deta ils of all of these t reatments are r ecorded in the subj ect’s notes and appropriate s ection 
of the e CRF. 
 
3.6.5    Bl ood donation  
 
Subjects should not donate blood while par ticipa ting in this study or for at l east 90 day s 
following the la st infusion of durvalumab, or until at l east 3 days af ter the la st administra tion of 
olapar ib. 
 
3.6.6    Other concomitant treat ment and medications  
 
1. No  othe r  chemotherap y  specified  outsi de  of  this  protocol,  hormona l  therap y 
(hormone replacement therapy [HR T] is accepta ble), or other novel agent is to be 
permitte d during the cour se of the study for any subj ect (the subj ect can receive a 
stable l ow dose of cor ticosteroids during t he study, a s per exclusion criteria above) . 
 
2. Live virus and bact erial vaccines should not be administ ered while the subj ect is 
receiving study med ication and during the 30-day follow-up per iod. An increased ri sk 
of infection re sulting from administ ration of live virus and bact erial va ccines has been 
observed w ith conventi onal chemothe rapy drugs; the effects w ith ola parib ar e 
unknown. 
 
3. Subj ects should avoid c oncomitant use of  drug s, herbal supplement s, and/or inges tion 
of foods known to modulate CYP3A4 enzy me activity from the time they enter t he 
screening p eriod until 30 days after the la st dose of study medi cation. In vitro data 
have shown that the principal enzym e responsible for t he forma tion of the 3 mai n 
metabolite s of olap arib is CYP3A4, and consequently, this restric tion is requi red to 
ensure subj ect safety. 
 
4.
 Concomitant  use  of  strong  CYP 3A  inhib itors  (eg,  itraconazole,  te lithromyc in, 
clarithromycin, ketoconazole, voriconazole, nefazodone, pos aconazole, r itonavir, 
34(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
lopinavir/r itonavir, indinavir, saquinavir, nelfinavir, boceprevir, telap revir) and 
moderat e CYP3A inhibit ors (e.g., ampre navir, aprepitant, atazanavir, ciproflox acin, 
crizotinib, dar unavir/r itonavir, diltiazem, erythromycin, fluconazole. Fos amprenavir , 
imatinib,  vera pamil) is not  allowe d. 
 
5. Concomita nt   use   of   str ong   CYP 3A   inducer s   (eg ,   phenytoi n,   rifampicin, 
carbamazepine, St. John’s Wort) and moderate CYP3A inducer s (eg, bosentan, 
efavirenz, et ravirine, modaf inil, nafcillin)  is not a llowe d. 
 
6. I mmunosuppre ssive medi cations should not be given concomitantly or given as a 
premedi cation prior to infusion. This includes but is not limited to systemic 
corticost eroids at doses not ex ceeding 10 mg/da y of prednisone or equivalent , 
methot rexate, azathioprine, and tumor necrosis factor-alpha (TNF- α) blocker s. 
 
The followi ng are a llowed exceptions: 
• Use of  immunosuppre ssive medi cations for t he management of durvaluma b-related 
AEs,  
• Short-t erm steroid pre medication for pa tients receiving durvalumab if required for 
documented hyper sensitivity re actions. 
• Use in patients w ith cont rast allergies as a premedi cation/p rep prior to scan s. 
• In addition, use of inha led, topi cal, and int ranasal cor ticost eroids is permitted. 
 
 
7. Subj ects who  are taking warfarin may par ticipate in this study;  however , it is 
recommended that prothrombin time (INR and AP TT) be monitore d carefully at l east 
once per week for the fir st month, then monthl y if the INR is stable. Subcutaneous 
hepar in is permitted. The reason( s) for the use, dose s, and dates of t reatme nt should 
be recorded in the subject ’s medi cal records and appropriate sec tion of the e CRF. 
 
8. All medi cations (pre scriptions or over -the-counter medi cations) continued at the st art 
of the trial or st arted during the study or until 30 days from the end of the la st protocol 
treatment and that are dif ferent from the study medi cation must be docume nted. 
 
3.7    Data Manage ment 
 
Data Management w ill be perf ormed by Duke C linical Res earch I nstitute  (DCRI). DCRI is 
responsible for the developme nt of  a 21 CFR Part 11-compliant el ectronic data manageme nt 
system. This system w ill include e CRF s creens, automate d data valida tion checks and a 
randomiz ation module. The data va lidation checks include checks for out-of- range and logicall y 
inconsistent data. 
 
The DCRI w ill be responsible for medi cal coding. Adver se events w ill be coded using DCRI’ s 
curre nt version of the medi cal dic tionar y for regulatory activ ities (Me dDRA) updated se mi- 
annually. The concomita nt medi cations w ill be coded using DCRI’s current ver sion of t he 
World Health  Organiza tion Drug Dic tionary Enhanced (W HO DDE) updated se mi-annually. 
35(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
Protocol specific data management ac tivities w ill be def ined in the Data Management Plan. 
Quality control pro cedures w ill be applied to e ach stage of data handling  to ensure that all dat a 
are reliable and have b een processed corr ectly. 
 
When all data have been coded, va lidated and locked, a c lean file will be decl ared. 
 
3.8    Evalu ation and calc ulation of variables  
 
The primary e fficacy outcome m easure is a s follow s: 
 
• PFS (progre ssion free survival) def ined as the time from randomiza tion to the firs t 
occurrenc e of disease prog ression (as det ermine d using RECIST 1.1 criteria and a ssessed 
by the Inves tigator) or death from any cau se on study. D eath on study is def ined as death 
from any cause w ithin 30 days of the la st dose of stud y treatment reg imen. Tumor 
progre ssion w ill be a ssessed locally at each s ite by the inve stigators according to RECIST 
1.1. No independent review of tum or progre ssion is planned. PFS w ith dis ease 
progression  de termined by iRECIST for pa tients on the combina tion arm will al so be 
examined in explora tory data analysi s. 
 
Th
e secondary e fficacy outcome m easures in all subj ects are as follow s: 
 
• OS (overall survival) d efined as the time from entry onto trial until death  from any cause. 
 
• ORR (overall response rate) def ined as the subj ects achieving Complete Response or 
Partial Response as def ined by RECIST 1.1. 
 
• CBR (clinical ben efit rate) defined as subje cts achieving Complete Re sponse, P artial 
Response or Stable disea se ≥ 24 w eeks 
 
   
3.9    Calc ulation or d erivation of efficacy varia ble(s) 
 
The followin g definitions and criteria (from RECIS T 1.1)  should be used for the base line 
evalua tions of  exis ting d isease, and for t he ongoing evalua tion of  tumor response s. All 
measurement s should be taken and recorded in metric nota tion, using a ruler or ca llipers. For 
the case of skin lesions, documenta tion (j pg file, pref erred) by col or photog raphy, and a 
measurement w ith a rule r to estima te the size of the lesion, is recommended. 
 
• Measurabl e disease - the pre sence of at l east one m easurable lesion. 
 
• Measurabl e lesions - lesions that can be accura tely m easured in at l east one dimension 
with longe st diameter (LD) 20 mm usi ng conventi onal t echniques or 10 mm  with spira l 
CT s can. Lymph nodes must be 15mm or g reater (by sp iral CT) in the shorte st diamete r 
to be considered m easureable. 
36(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
• Non-measurabl e lesions - all other lesions, including small lesions (LD <20 mm w ith 
conventional techniques or <10 mm, Lymph nodes <15mm SD w ith spiral CT s can), ie , 
bone lesions, asc ites, pleura l/pericardial effusi on, cystic lesions, and also abdomina l 
masses that are not confirmed and followe d by imaging t echnique s. 
 
Conventiona l CT should be p erformed w ith cuts of 10 mm or le ss in s lice thickne ss 
conti guously . Spiral CT should be perf orme d using a 5-mm con tiguous reconstruc tion algor ithm.  
 
All imagi ng methods should be perf ormed a ccording to ins tituti onal standards w ith each subj ect 
having consistency of methods beginning from base line through the course of the study. 
 
3.9.1    Evalu ation of Be st Overall Respon se 
 
The best overall response is the be st response recorded from the s tart of the t reatme nt until 
disease progre ssion and is det ermined as per Tables 10 and 11. 
 
To be conside red a re sponse, CR or PR must per sist for a minimum of 4 w eeks. If, at the time 
of tumor response evaluation, e ither a PR or CR is obs erved, the same radiographic study should 
be repeated four w eeks later for confirma tion of response. After this confirma tory study, 
subjects should return to the schedule of evalua tions as pre viously des cribed. 
 
 
 
 
4    STUDY PROCE DUR ES AND A SSES SMENTS  
 
The schedul e of assessments is provided in Appendix A. Descriptions of the scheduled 
evalua tions are outlined below and complete informa tion on study drugs and dosing is provided. 
 
Before study entry, throughout t he study, and at the follow-up evalua tion, var ious c linical a nd 
diagnos tic labora tory evalua tions are outlined. The purpose of obtaini ng these deta iled 
measurements is to ensure adequate s afety and tol erabilit y assessments. C linical eva luations and 
labora tory studies may be repeated more frequently if clinically indicated. This study will use  
local s ite labs for labora tory testing and for s afety labora tory evalua tions; biom arker specimens 
collected wi ll be store d at study s ites until end of study then shipped  to the D uke Pathology 
central biore pository for future research. 
 
 
 
4.1    Subject enrollment and randomization  
 
4.1.1     Informed consent  
 
Inves tigators must ensure that subje cts are cl early and full y informed about the purpose , 
potential r isks, and other cr itical issues reg arding this  clinica l stu dy for which the y are 
volunt eering to p articipate. 
 
Before any study procedure s are performed, poten tial subj ects w ill have the outline of the stud y 
described to them, and they w ill be given a written informed consent document to read. If the y 
consent to par ticipat e in the study, they w ill indi cate that consent by signing and da ting the 
informed consent document in the pre sence of study personnel. Any subj ect who signs th e 
37(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
 consent form w ill be con sidered a “scr eened” subj ect. 
 
4.1.2    S creenin g Proce dures  
 
After written informed consent is obtained a ccording to ICH GCP and lo cal regula tions, t he 
subject’s e ligibility for the study and base line dis ease status w ill be evaluated. This will occur 
in a s creening visit duri ng which the following w ill be evaluated and docume nted w ithin 14 da ys 
prior to fir st dose of study drug(s). 
 
Inves tigations, such as CT or MR I scans that have been pe rformed as par t of routine c linica l 
practice, can be used as par t of the scr eening pro cess if p erformed w ithin 28 days of first dose 
of study tr eatment; howe ver, no non-standar d of care inve stigations or te sts that are study 
specific and requi red for s creening may be pe rformed prior to signature of the informed consent 
form. 
 
The followi ng base line informa tion should be obtained w ithin 28 days prior to ra ndomiz ation: 
 
• Demographic data and medi cal history, including pre vious and cur rent dis eases a nd 
medi cations, and confirma tion of a ll prior trea tments for meta static breast cancer, 
including platinum based t reatment requirements of inves tigator choi ce. 
 
• Check availability of archival tumor tissue  sample or new tum or biopsy if archival tissue 
unava ilable 
 
• Base line adver se events to document pre-ex isting  toxicity from prior t reatment (assesse d 
using CTCAE v4.03) 
 
• Tumor response to pla tinum based chemotherapy, evalua tion by CT or MRI (as def ined 
by inve stigator a ssessment) 
 
• Phy sical exa mination including the a ssessment of height, weight, pul se rate and blood 
pressure and BMI. 
 
•       Eastern Coopera tive Oncology Group (ECOG) pe rformance status 
 
•       Blood testsb 
 
 Full blood count (CBC w ith di fferential) 
 
 U& E: serum c reatinine ( SCr), urea, K+, Na+, glom erular f iltration rate 
assessment 
 
 Liver func tion test: B ilirubin, ALP, AST/AL T, albumin 
 
•       Radiologi cal inve stigations 
 
 CT or MRI scan to a ssess dis ease (thorax, abdomen and pelvi s) 
 
•       Other tests 
 
 P regnancy tests 
 
See Appendix G for addi tional requirements for Korean s ites only. 
 
Wher e labora tory inves tigations have not been perf ormed w ithin the 7-day p eriod pri or to 
starting treatment, they must be repeated on day 1 of cycle 1. 
 
4.1.3   Base line docum entation of “target ” and “non-target ” lesions  
38(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
All m easurable lesions (nodal and non-nodal) up to a max imum of  five lesions in total (and a 
maximum of 2 lesions per organ), representa tive of all involved organs, should be identified a s 
target le sions and recorded and m easured at base line. Target lesions must be 10 mm in t he 
longe st diameter to qualify, or 15 mm in the short diamete r for lymph node s. Target lesions 
should be sel ected on the basis of their s ize (lesions w ith the longe st diamet er) and their 
suitabilit y for accurate repeated m easurements (either by imaging techniques or cl inical 
assessments). 
 
A s
um of the longe st diameter (LD) for all target lesions will be calculated and reported as t he 
baseline sum LD. The base line sum LD w ill be used as the reference by which to charact erize 
the obj ective  tumor response. 
 
All other lesions (or s ites of dis ease) should be identified as non-target lesions and should al so 
be recorded at base line. M easurement s of these lesions are not required, but the presenc e or 
absence of e ach should be noted throughout follow-up. 
 
4.1.4    En rollment proce dures  
 
Subjects der iving c linical benef it (CR / PR / S D) with platinum-based therap y will be 
randomiz ed to each of the t reatment arms (olapar ib or olaparib in combina tion w ith durvalumab) 
through the use of a stratified per mute d block randomization in a 1:1 ratio to ensur e within-stratum 
balance of cha racteristics betw een t reatment arm s. The stratification  will be based on line of  
chemotherapy and b y site.  Randomiza tion will be us ed to allocate subj ects to either the olap arib 
or olapar ib in combinat ion w ith the durvalumab arm, and compar isons bet ween tr eatment 
regimens are p
lanned. The purpose of randomiz ation is to reduce bias due t o subj ect sel ection  into 
either trea tment arm. 
 
There are five in
stitutions par ticipating as study  sites in three countries including USA, 
Singapore, and South Korea.  E ach s ite w ill comple te an e ligibility chec klist and enrollme nt 
must be submitted and approved prior to t he randomizat ion of  any subj ect. The deta ils of this 
procedure is provided in the site initia tion materials. 
 
4.1.5   Post-p latinum chemoth erapy tumor evaluation  
 
Initial tumor a ssessment to a ssess for response to pla tinum chemotherapy w ill be perf ormed as 
per stand ard of c are following at least three 3- weekly (q21 day) or six 1-weekl y dos es of 
platinum chemotherapy. A ttempts  should be made to minimiz e time off t reatment to le ss than 
3 w eeks. Any m easurable dis ease must be documented at s creening and re-a ssessed at tumor 
evalua tion. M easurable dis ease is not requi red to go on study. Response a ssessments w ill be 
performed by the Inves tigator on the basis of physi cal exa mina tions and imaging scans. 
Eligibilit y requi res stable dis ease (SD), par tial response ( PR) or complete response ( CR) p er 
investigator a ssessment to the pla tinum therapy. 
The same imag ing method used at s creening/base line must be maintained throughout the study . 
Comput erized  tomog raphy  (C T)  scans  ar e  the  pre ferred  imaging  modality  fo r  tumor 
assessments. Tumor a ssessments should include a diagnos tic qua lity contrast-enhanced CT scan 
of the chest, abdomen, and pelvis at base line. C omputerized tomog raphy (C T) scans of the neck 
should be included if ther e is c linicall y indi cation. Subsequent tumor a ssessments should include 
CT s cans of t he chest, abdomen, pelvi s, and other known s ites of disease. In addition to the 
39(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
 scheduled protocol scans, CT s cans may be performed at the Inve stigator’s discre tion at an y time 
if progre ssive dis ease is suspected. 
 
In subj ects for whom a CT s can is cont raindicate d because of an a llergy to IV radiographi c 
contrast, both CT scan of the che st without contra st and a magne tic resonance imaging (MRI ) 
scan w ith contrast of the abdomen and pelvis and neck if c linically indi cated are recommended; 
MRI scans may be performed in lieu of CT s cans. Subsequent tumor a ssessments should include 
MRI scans of the chest, abdome n, pelvi s, and other known s ites of disease. The CT or MR I 
scans may be repeated at the Inve stigator’s dis cretion  at any time if p rogre ssive disease i s 
suspected. 
 
At the Investigator’s dis cretion and if c linically indi cated, other methods of a ssessment of 
measurable dis ease per RECIST 1.1 may be used (eg, bra in scans using CT or MRI) in addition 
to those listed above. Additiona l procedures for tumor a ssessment should be pe rformed a s 
clinically indi cated. 
 
4.1.6      Procedures f or randomization  
 
Subjects w ith CR, PR, or SD by inve stigator assessment following minimum requirements in 
inclusion criteria of plati num-based chemotherap y are elig ible to c onsent and complet e 
screening activitie s. Subj ects who m eet a ll elig ibility requi rements w ill be randoml y allocated 
to each of the t reatment arms (olapar ib or olap arib in combina tion w ith durvalumab).  
 
Subjects w ill be a llocated to each of the trea tment arms (olapar ib or olap arib in combina tion 
with durvalumab) through the use of a st ratified p ermuted block ra ndomization in a 1:1 ratio, to 
ensure w ithin-st ratum bal ance of cha racteristics bet ween trea tment arms. Randomiz ation wil l 
be stratified by line of che moth erapy (1st vs 2nd) and by s ite. 
 
4.1.7     Procedures f or handl ing ine ligible or s creen-fail s ubject s 
 
Subjects who signed the study informed consent form but are consid ered ine ligibl e after 
screening w ill be considered as scr eening failures, and da ta will be handled as follow s:  The 
demographi c informa tion, informed consent, and inclusion/exclusion criteria will be collect ed 
for scr een fa ilure subj ects. No other data w ill be collecte d for subj ects w ho are screen failures 
unless the subj ect experienced a  serious adverse event during the sc reening phase that i s poss ibly 
related to a study pro cedu re. 
 
4.2     T reatments  
 
Subjects w ill continue on study drug( s) until obj ective d isease prog ression, as long as in the 
Inves tigator’s opinion they are benef iting from t reatment and they do not m eet any other 
discontinua tion criteria. 
 
4.2.1    Identity of investigational product( s) 
 
The AstraZeneca Pharm aceutic al Development R&D Supply Chain w ill supply olapar ib and the 
durvalumab to the Inves tigator/sponsor’s dispensing vendor. This vendor w ill distribut e drug 
supply to the par ticipa ting sites. 
40(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
Tabl e 2: Identity of Investigational Product  
 
Inve stigational p rodu ct Dosage form and st rength  
Olaparib 150 m g oral tabl et and 100mg oral tablet  
(100mg for do se reductions only) 
Durvalum ab 1500 mg intra venous 
a Descr iptive informatio n for olapari b can be found in the Investigator’s Brochure 
 
4.2.2     Olapar ib 
 
Olapar ib (AZD 2281) (as f ilm-coated tablet formulation) is intended for ora l administra tion. The  
tablet monotherapy dose and the dose that w ill be used in this study is 300 mg  bid taken 
continuously in 28 day cycle s. 
 
4.2.3    Olapar ib: dose s and treatment regimens  
 
For a ll cente rs, olapar ib tablets w ill be packed in high-density polyethylene ( HDP E) bottles wit h 
child-resistant closure s. Each dosi ng containe r will contain 32 tablets and desi ccant . Multiple 
bottles of study trea tment may be required for dispensing in order to make up the desi red dose. 
 
Olapar ib will be di spensed to subj ects on Day 1 and approx imatel y every 28 days ther eafter 
until the subj ect complete s the study, the subject w ithdraw s from the study or closure of t he 
study. 
The olaparib tablets should be swa llowe d whole and not che wed, crushed, di ssolved, or divided. 
The effect of food on olapar ib tablet has been inves tigated. Co-administ ration w ith food slowe d 
the rate of absorption (tmax de layed by 2.5 hour s and Cmax reduced by 20%), however food  
did not signifi cantl y affect AUC, theref ore olaparib tablet formula tion can be given w ithout 
regard to food. 
 
If vo miting  occurs shor tly after the olapar ib tablets are swallowe d, the dose should onl y be 
replaced if all of t he intact tablets can be seen a nd counted. Should any subject enrolle d on t he 
study mi ss a scheduled dose for whatever reason (eg, a s a result of f orgetting to  take the tablet s 
or vomiting), the subje ct will be a llowe d to take the scheduled dose up to a max imum of 2 hour s 
after that scheduled dose time. If longer than 2 hours after the scheduled d ose time, the missed 
dose is not to be taken a nd the subj ect should take th eir a llotted dose at the next scheduled time. 
 
Subjects will continue with olaparib until obj ectiv e disease progre ssion (determined by RE CIST) 
as long as in the In vestigator’s opinion they are bene fiting from treat ment and the y do not  meet 
any other discontinuation  criteria. 
 
4.2.4    Management of toxicity of olaparib  
 
Any toxicity obs erved during the cour se of the st udy could be managed by int erruption and/ or 
dose reduction of the dose if d eemed appropriate by the Inves tigator. Repeat dose interruptions 
are allowed as required for a max imum of 14 days on each oc casion. If the int erruption is any 
41(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
longer than thi s, the sponsor or their designe e must be informed. Olapar ib must be int errupted 
until the subj ect recovers completel y or the toxicity rever ts to the National Cancer I nstitute 
(NCI) Common T erminology Cr iteria for Adver se Events ver sion 4.03, grade 1 or le ss. 
 
Wher e toxicity reoccur s following re-cha llenge with olap arib, and wher e further dos e 
interruptions are conside red inadequate for management of  toxicity, then the subj ect should be 
considered for dose reduc tion or must per manently disconti nue tr eatment w ith olapar ib. 
 
Treatment must be int errupted if any NCI-CTCAE g rade 3 or 4 adv erse event occurs that the 
Inves tigator consider s to be related to administ ration of olapar ib. 
 
All dose reductions and int erruptions (includi ng any missed doses), and the reasons for t he 
reductions /interruptions are to be recorded in the el ectronic case record form (eCRF) . 
 
Management of ane mia 
 
Adverse  event s  of  anemi a CTC AE  grade  1  or  2  (Hemoglobi n  [Hb]  >8 g/dl )  should  be 
inves tigated and managed as deemed appropriate by the Inves tigator with or without int erruption 
of study drug or change in dose, taking into acc ount pre vious histor y of anemia. Co mmon  
treatabl e  cause s  of  ane mia (eg,  iron,  vit amin  B12  or  folat e  deficiencies,  and 
hypothyroidism) should be excluded. In some cases, management of anemia ma y require blood 
transfusions. Howe ver, if a subj ect develops an emia CTCAE g rade 3 (Hb <8 g/dl) or worse , 
study tr eatment should be interrupted for up to max imum of 4 weeks to a llow for bone m ar row 
recovery, and the subj ect should be managed appropriately. Study tr eatment can be restarted a t 
the same dose if Hb has recove red to >10 g/dl or base line. Any subsequently required ane mia 
related interruptions, considered likely to be dose related, or coexistent w ith new ly develope d 
neutropenia, and or thrombocytopenia, w ill require Olap arib study trea tment dose reductions to 
250 mg bid as a fir st s tep and to 200 mg bid as a s econd step. 
 
If a subj ec t has been tr eated for ane mia with multiple  blood t ransfusions w ithout study trea tment 
interruptions and becomes blood-t ransfusion dependent—as judged by t he Inves tigator— stud y 
treatment should be per manently discontinued. 
 
Management of neu tropen ia and le ukop enia 
 
An adver se event of neutropenia and leukopenia should be managed as de emed appropriate b y 
the Inve stigator with close  follow-up and interruption of  study drug if C TC grade 3 or wor se 
neutropenia o ccurs. Primary prophylaxis w ith granulocyte colony- stimulating factor (G- CSF) 
is not recommended; howe ver, if a subj ect develops febrile neutrope nia, Olaparib stud y 
treatment should be stopped and appropriate management including G-CSF should be given 
according to local hospita l guide lines. Please note that G- CSF should not be used w ith in at least 
24 h of the la st dose of Olapar ib study treatment. 
 
Olapar i b tr eatment can be restarted at the same dose if an adver se event of neutropenia or 
leucopeni a  hav e  been  recove red  up  to  C TC  A E  gra de  >1  (absolut e  neutrophi l  count 
42(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
>1.5 x 109/L). Growth factor support should be stopped at l east 24h bef ore rest arting study drug 
(7 days for pegylated G- CSF). 
 
Any subsequent int erruptions w ill require study tr eatme nt dose  reduc tions to 250 mg bid as a 
first step and to 200 mg bid as a s econd step for a 300 mg monotherapy star ting dose. 
 
Management of thrombocytope nia 
 
An adver se event of thrombocytopeni a should be managed as deemed appropriate by the 
Inves tigator. If a subj ect develops thrombocytopenia CTCAE g rade 3 or worse, study t reatment 
should be int errupted for a max imum of 4 weeks. In some cases, manageme nt of 
thrombocytopeni a may require platelet t ransfusions. Platelet t ransfusions should be done 
according to local hospit al guide lines. 
 
Man
agement of prolonged hematological toxici ties w hile on st udy treatme nt 
 
If a subj ect develops prolonged hematologi cal toxicity such as: 
 
• ≥2-week int erruption/delay in study trea tment due to CTC grade 3 or wor se anemia 
and/or development of blood t ransfusion dependence 
• ≥2-week interruption/d elay in study treatment due to C TC grade 3 or wor se neutropenia 
(absolute neutrophil count < 1 x 109/L) 
• ≥2-week  interruption/de lay  in  stud y  treatment  due  to  C TC  g rade  3  or  wor se 
thrombocytopenia (platelets <50 x 109/L) 
 
Weekl
y differential blood counts includi ng re ticulocytes (calculat e reticulocyte index (RI), RI 
= reticulocyte count x hema tocrit (Hct)/normal Hct; a value of 45 is usually used for norma l 
Hct), and a p eripheral blood sm ear should be perf ormed. If any blood parame ters remain 
clinically abnormal after 4 weeks of dose inte rruption, the subj ect should be referred to 
hematologi st for further inves tigations. Bone marrow analysis and/or blood cytogene tic analysi s 
should be considered at this stage accordi ng to standard hematologi cal practice. 
 
Development of a confirmed MDS or other clonal blood di sorder should be reported as an SA E. 
Study t reatment should be discontinued if dia gnosis of MDS is confirmed. 
 
The dose of olapar ib must not be adjusted under any other ci rcumstan ces unle ss the s ite 
Principal Inves tigator (PI) has provided a prior agr eement. 
 
Management of neu tropenia, le ukopen ia and thrombocytopen ia 
 
Toxic ity Study t reatment do se adj ustment 
 
CTCAE Grade 1- 2               Inv estigator judgment t o continue treatment or if dose interrup tion, thi s 
shoul d be for a maximum of 4 w eeks; appropriate supportive tr eatment 
and ca usality inv estiga tion 
43(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
Toxic ity Study t reatment do se adj ustment 
 
CTCAE Grade 3-4 Dose inte rruption until r ecovered to CT CAE gr 1 or bett er for a m aximum 
of 4 w eeks. If r epeat CTCA E grade 3-4 occurrence , dose reduce ol aparib 
to 250 mg t wice da ily as a first step and 200 mg twi ce daily as a second 
step 
 
 
 
Olaparib Dose reduct ions for st udy treatme nt 
 
Initial D ose Dose red uction 1 Dose red uction 2 
300mg twi ce daily 250mg twi ce daily 200mg twi ce daily 
 
 
Management of new or worse ning pulmonary symptoms  
 
If new or worsening pulmonary symptoms (eg, dyspnea) or radiologi cal abnorma lity occur s, an 
interruption in olapar ib dosing is recommended, and a diagnos tic workup (including a hig h 
resolution CT s can) should be performed to exclude pneumonitis. Following investiga tion, i f 
no evidence of abnormalit y is obs erved on CT imaging and symptoms re solve, then olap arib 
treatment can be restarted, if deemed appropriate by t he Investigator. If si gnificant pulmonar y 
abnorma lities are identified, the se need to  be discu ssed w ith the site PI. 
 
Ma
nagement of nausea and vomit ing 
 
Events of nausea and vo miting are known to be a ssociated w ith olapar ib treatment. In stud y 
D0810C00019, nausea was reported in 71% of the olapar ib-treated sub jects and 36% in t he 
placebo-treated subje cts; vomiting  was reported in 34% of t he olaparib-treated subjects and 14% 
in the pl acebo-treated subj ects. These event s are gen erally of mild to modera te (CTCAE g rade 
1 or 2) sever ity, int ermittent, and manageable on continued t reatment. The first onset gen erally 
occurs in the fir st month of t reatment, w ith the inci dence of nausea and vo miting  not showi ng 
an incr ease over t he treatment cycle s.   Both nausea and vomiting  were reported to be 
intermittent for the majority of pa tients and can be managed by dose interrup tion, dose reduction 
and/or antieme tic therapy. 
 
No routine prophyl actic anti-eme tic trea tment is required at the start of study trea tment; 
howe ver, subj ects should receive appropriate anti-eme tic treatment at the fir st onset of nause a 
or vomiting  and a s required ther eafter, in accordance w ith local trea tment pr actice guide lines. 
 
Renal Impair ment 
 
If subsequent to study entry and w hile still on study therapy, a pa tient’s e stimated CrCl falls 
below the th reshold for study inclusion ( ≥51 ml/min ), retesting should be pe rformed promptly. 
44(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
A dose reduction is recommended for pa tients who develop mode rate renal impairment 
(calculated creatinine clearance by Cockcroft-Gault equa tion of bet ween 31 and 50 ml /min) f or 
any reason during the cour se of the study: the dose of olapar ib should be reduced to 200mg BD. 
 
Because the CrCl deter mina tion is only an estimate of renal func tion, in instances where t he 
CrCl falls to bet ween 31 and 50 mL /min, the inves tigator should use his or her disc retion in 
determining whether a d ose change or discontinua tion of therapy is wa rranted. 
 
Olapar ib has not been studied in patients w ith sever e renal impairment (c reatinine clea rance 
≤ 30 ml/min)  or end-sta ge renal disease; if pa tients develop severe impairment or end s tage 
disease is it recommended that olapar ib be discontinued. 
 
Hepatic Impair ment  
 
If subsequent to study entr y and while on study therapy, t he patient develops hepa tic impairment , 
the inves tigator should make every a ttempt to iden tify the under lying reason f or the  impairment. 
 
Olapar ib can be a dminist ered to patients w ith mild  or moderate hepa tic impairment (C hild-Pugh 
Classification A or B) with no dose adjus tment. Olapar ib has not been studied in pa tients wi th 
sever e hepa tic impair ment and is NOT recommended for use in these pa tients. 
 
  
4.2.5    Durvalu mab  
 
Durvaluma b should be given at l east 1 hour after the subj ect has taken their olapar ib morning 
dose. Durvalumab w ill be administ ered as an IV infusion over 60 minute s (+/- 5 minute s) at a 
dose of 1500 mg every 28 day s. 
 
Subjects a llocated to the combina tion arm in the study w ill receive durvalumab via I V infusion 
at a dose of 1500 mg every 28 days in addition to olapar ib tablets 300 m g bid. T reatment w ith 
durvalumab  w ill  commenc e  on  Day 1  of  each  28  da y  cycle s  and  wil l  continue  on  t he 
recommende d schedule until progre ssion of dis ease, unac ceptable toxicity, w ithdrawal of 
consent, or other reasons to discontinue t reatment occur. Disea se prog ression require s 
confirma tion, t reatment w ith durvalumab w ill continue be tween the initial a ssessment of 
progression and confirma tion of  prog ression.  If prog ression is not confirmed, then t he subj ect 
should continue on study t reatment and on tr eatme nt assessment s. 
 
4.2.6    
Durvalu mab: drug pr eparation  
 
The Inves tigational Products Supply sec tion of AstraZene ca/MedI mmune wi ll suppl y 
durvalumab as a 500-mg vial solution for infusion after dilution. The solution contains 50 
mg/mL durvalumab, 26 mM histidin e/histidine-hydrochloride, 275 mM t rehalose dihydrate, 
and  0.02% (/volume )  polysorbate  80;  i t  has  a  pH  of  6.0.  The  nomina l  fill  volum e  is 
45(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
10 mL.  Inves tigational product vials are stored at 2°C to 8°C (36°F to 46°F) and must not be 
frozen. Durvalumab must be used w ithin the individually a ssigned expiry date on t he label. 
 
For pa tients weighing >30 kg, a fixed dose of 1500 mg Q4W durvalumab (equivalent to 20 
mg/kg Q4W) (based on an average body WT of 75  kg) should be pre pared. For subje cts ≤30 kg 
body weight, dose is de termined usi ng body weight, calcula ting the stock volume of durvalumab 
to achieve the a ccurate dose accordi ng to Ap pendix D. If a pa tient weighs ex actly 30 kg or le ss, 
then pa tient should receive weight-based dosi ng for durvalumab. 
 
Th
e dose of durvalumab for administ ration must be pre pared by the Inves tigator’s or s ite’s 
designated IP manager using aseptic technique .  Total time from need le punc ture of th e 
durvalumab vial to the st art of administ ration should not ex ceed: 
 
• 24 hour s at 2°C to 8°C (36°F to 46°F) 
 
• 4 hour s at room temperature 
 
If in-use storage time ex ceeds the se limits, a  new dose must be p repared from new vials. Infusion 
solutions m ust be  allowe d to equilibra te to room temperature prior to commenceme nt of  
administ ration. 
 
No incompa tibilitie s between durvalumab and polyvinylchloride or polyol efin IV bags hav e 
been obs erved. Dose of  1500mg durvalumab for pa tients >30 kg will be ad minist ered usi ng an 
IV bag containi ng 0.9% (w/v) sa line w ith a final durvalumab con centration ranging from 1 to 
20 mg/mL,  and de livered through an IV admi nistration set w ith a 0.2- or 0.22- μm in-line filter. 
 
Remove a volume of IV solution from t he IV bag equal to t he calculated volume of durvalumab 
to be added to t he IV bag prior to addition of durvalumab. Next, the volume of durvalumab (ie, 
30.0 mL for 1500 mg of durvalumab) is added to the IV bag such that final concentra tion is 
within 1 to 20 mg /mL (IV bag volumes 100 to 1000 mL).  Mix the bag by gentl y inver ting to 
ensure homogeneity of the dose in the bag. 
 
4.2.7    
Durvalu mab: D oses and treat ment regimens 
 
Patient we ight at base line should be used for dosing calculations in patients ≤30 kg unle ss there 
is a ≥10%  change in weight.  Dosi ng day weight can be  used for dosing calculations inst ead of 
baseline weight per ins titutional standar d. 
 
For pa tients ≤30kg, calculat e the dose volume of durvalumab and number of vials needed fo r 
the subj ect to achieve the accurate dose according to Appendix D. 
 
Durvalumab w ill be ad minist ered at room temperature (approx imately 25°C) by controlle d 
infusion via an infusion pump into a per iphera l or centra l vein. Followi ng p reparation of 
durvalumab, the entire content s of the IV bag should be administ ered as an IV infusion ove r 
approx imatel y 60 minutes ( ±5 minutes), usi ng a 0.2, or 0.22- μm in-line filter. Less than 55 
minutes is considered a devia tion. 
46(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
The IV line will be flushed w ith a volume of IV solution (0.9% [w/v] sa line, (possibl y using 
dextrose as diluent) equal to the pr iming  volum e of the infusion set used after the contents of 
the IV bag are fully ad ministered, or complete t he infusion accordin g to ins titutional pol icy to 
ensure the full dose is ad minist ered and document if t he line was not flushed. 
 
Standar d infusion time is 1 hour.  However , if ther e are interruptions during infusion, the tota l 
allowe d time should not ex ceed 8 hours at room temperature . The table below summar izes time 
allowa nces and temperature s. 
 
Ta
ble 3: Durvalu mab hol d and infu sion times  
 
Maximum time from  need le puncture to star t 
of ad ministration 
 
Maximum time for IV bag infusion, includi ng 
interruptions 4 hours at  room temperature, 24 hours at 2°C to 
8°C 
 
8 hours at  room temperature 
 
  
In the event that e ither preparation time or infusion time exceeds the t ime limits  outlin ed above , a 
new dose must be pre pared from new vial s. Durvalumab does not contain pre serva tives, and any 
unused por tion must be dis carded. 
 
4.2.8    Durvalu mab: moni toring of do se adm inistration  
 
Subjects will be monitored before , during and after the infusion w ith assessment of vital signs 
at the times specified in the Schedule of Asse ssme nt. Subj ects are monit ored (pul se rate, blood 
pressure) every 30 minutes during t he infusion period (includi ng times wh ere infusion ra te is 
slowe d or temporarily stopped). 
 
In the event of a ≤ Grade 2 infusion- related r eaction, the infusion rate of study drug may b e 
decreased by 50% or inte rrupted until re solution of the event (up to 4 hours) and re- initiated at 
50% of t he initial rate until comple tion of the infusion.  For subjec ts with a ≤ Grade 2 
in fusion- related re action, subsequent infusions may be admi nistered at 50% of the initia l 
rate. Aceta minophen and/or an antihista mine (eg, diphenhyd ramine) or equivalent medi cations 
per institution al standar d ma y be administered at the dis cretion of the inve stigator.  If t he 
infusion- related reac tion is Grade 3 or highe r in sever ity, study drug w ill be discontinued. The 
standar d infusion time is one hour, howe ver if ther e are interrup tions during infusion, the tota l 
allowe d time from infusion st art to comple tion of  infusion should not ex ceed 8 hours at room 
temperatu re,  w ith max imum total ti me at room te mperatu re not ex ceeding 8 hours (otherw ise 
requires new infusion preparation). 
 
As w ith any antibody, a llergic reactions to dose ad ministra tion are possible. Appropriate drug s 
and medic al equipment to t reat acute anaphyl actic re actions must be immediately ava ilable, and 
study personnel must be t rained to r ecogniz e and t reat anaphylaxi s.  The  study site must have 
immedia te access to emergency resuscitation teams and equipment in addition to the a bility to 
admit subj ects to an inte nsive care unit if necessary . Foll owing preparation of durvalumab, the 
47(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
entire contents of t he IV bag should be administered as an IV infusion over approx imately 60 
minutes (+/- 5 minutes). 
 
4.2.9 Management of toxicity of durvalumab  
 
Durvalumab is an anti -PDL1 anti body that binds w ith high affinity and specificit y to PD- L1 
and blocks its bindi ng to PD-1 and CD-80; thus, it promotes anti-tumor immunity and tumor- 
cell killin g. Potential risks based on this m echani sm of  action of durval umab and related 
molecules include immune-mediated r eactions such as ent erocolitis, d ermatitis, hepa totoxicit y 
or hepa titis, endocr inopathy , neuropathy, and pneumonitis.  This cla ss of drug has a wid e 
spectrum of immune- mediated re actions that have been considered inflammatory in natu re and 
can affect any organ of t he body. 
 
Th
e followi ng general guidance should be foll owed for management of toxic ities. 
 
• Treat e ach of the toxic ities w ith max imum suppor tive care (includi ng holding t he agent 
suspected of causing the toxicity where requi red). 
 
• If the symptoms promptly re solve w ith supportive c are, consideration should be given 
to continuing the same do se of durvalumab along w ith appropriate continuing suppor tive 
care. If medic ally appropriate, dose modifi cations are per mitted for durvalumab. 
 
• All dose modifi cation should be documented w ith cl ear reasoni ng and documenta tion of 
the approach taken. 
 
Imm un
e-related adverse events  
 
Based on the m echani sm of action of durvalumab that leads to T-cell activation and 
prolifera tion, there is a possibility of observing immun e-related A Es (irA Es) during th e 
conduct of this study. Potential i rAEs include immun e-mediated ent erocolit is, dermatitis, 
hepa titis, and endocr inopathie s. Subj ects should be monitore d for signs and symptoms of 
irAEs. In the absence of an a lternate e tiology (eg, infection or PD) signs or symptoms of 
enterocolitis,  dermatitis, hepa titis, and endocr inopathy should be consider ed to be immune- 
related.  Followi ng the first dose of durvalumab, subsequent administ ration of durvalumab 
can be modified based on toxic ities obs erved and as des cribed in Table 4. 
 
Tabl e 4: Durvalu mab d ose modi fication due to toxicity 
 
See Appendix F for To xicity Management Guidelines 
 
In addition to the dose modifi cations shown, it is recommended the manag ement guide lines 
for irAEs are followe d; these modifi cations are presented in Table 5 below: 
 
 
     
48(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
Tabl e 5: Management of imm une- related adver se events  
 
1 Subject evaluation to identify any alternative etiology 
2 In the absen ce of a clear alternative etiology, all events of an inflammatory nature shou ld be 
consider ed to be immune-relat ed 
3 Symptomatic and topic therapy shou ld be considered for low-grade events 
4 Systemic corticosteroids should be considered for a persistent low-grade event or for a severe event 
5 More potent immunosupp ressors should be considered for events not responding to systemic 
steroid s. 
 
  
 
 
Pneumonit is 
 
Pneumonitis h as been reported w ith use of anti-PDL1 / anti-PD-1 antibodie s. Initial work up 
should incl ude a  high resolution CT s can to rule out infection and pul se oximetry. Additiona l 
assessments are to include pulmonary func tion tests and blood gase s. Pulmon ary consulta tion 
is recommended. For Grade 2 pneumonitis that does not resolve to ≤Grade 1 within  3 days 
of maximal   support ive   care   (including   steroids)   or   ≥Grade 3   pneumonitis,  per manentl y 
discontinue durvalumab. 
 
Infusion Reactions 
 
Subjects w ill be monit ored during and after the infusion w ith assessme nt of vital signs (blood 
pressure [BP] and pulse) at the beginning of the infusion, every 30 minutes during the infusi on, 
at  the  end  of  the  infusion,  a nd  at  30  and  60  minutes in  t he  1-hour  obs ervation  per iod 
post-infusion. If the infusion takes longer than 60 minutes, then BP and pul se measurement s 
can be done more f requently if c linically indi cated. 
 
In
 the event of a ≤Grade 2 infusion-related reaction, the infusion rate of durvalumab may be 
decreased by 50% or inte rrupted until resolution of the event (up to 4 hours) and re- initiated 
at 
50% of the initial rate until comple tion of  the infusion. If, following 4 hours of int erruption, 
there is a per sistent Grade 2 toxicit y despite the use of appropriate medi cations such as 
antihista mines or parac etamol, then study tr eatment should be discontinu ed. If, following 
4 hours of int erruption, ther e is a decr ease to Grade 1, then t he drug may be re-introduced if 
it does not pre sent an increased ri sk to the subj ect. 
 
Hyper
sensitivity react ions 
 
Hypersensitivity r eactions, as well as infusion- related r eactions, have been reported w ith 
anti-PDL1. As w ith any antibody, a llergic reactions to dose a dminis tration are possible. 
Appropriate drug and medi cal equipment to t reat acute anaphyl actic reactions must be 
immediately ava ilable, and study per sonnel must be t rained to recognize and t reat anaphylax is. 
The study s ite must have immediate access to e mergency resuscitation teams  and equipment in 
addition to the a bility to a dmit subj ects to an intensive care unit if necessary. 
 
49(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
 Acute a llergic re actions may occur, ma y be seve re, and may results in d eath. Acute a llergi c 
reactions may include hy potension, dyspnea, cyanosi s, respiratory failure, ur ticarial, prur itus, 
angioedema, hypotonia, ur ticarial, arthralgia, bronchospasm, wheeze, cou gh, dizziness, fatigue, 
headache, hypertension, myalgia, vomiting, and unre sponsivene ss. 
 
Hepatotoxicity 
Increased transa minases have been reported during trea tment w ith anti--PDL1. 
Other AESIs obs erved w ith durvalumab include: 
• Colitis  
• Neuropathy / neuromuscular toxicity (i.e. events of encepha litis, peripheral motor and 
sensory neuropathie s, Guillain-Bar ré, and myasthenia gravi s) 
• Endocr inopathy (i.e. events of hypophys itis, adrenal insufficiency, and hyper- and 
hypothyroidism) 
• Dermatitis 
• Nephritis 
• Pancreatitis 
Further informa tion on the se risks (e.g. pre senti ng symptom s) can be found in the curre nt 
version of the durvaluma b Inves tigator Brochure. 
 
4.2.10  Labe ling 
 
Labels w ill be pre pared in accordance w ith Good Manufacturing Prac tice (GMP) and loc al 
regula tory guide lines. The labe ls will fulfil G MP Annex 13 requirement s for labe lling. Lab el 
text w ill be translated into local language. 
 
Each bot tle of olap arib will have an inve stigational product label p ermanentl y affixed to the 
outside stating that the mat erial is for c linical trial /investigational use only and should be ke pt 
out of reach and sight of childre n. The label w ill include the dosi ng instructions to be review ed 
at the time of dispensing. 
 
The label w ill include the f ollowing information: 
 
•           Blank lines for quantity of tablets to be taken 
 
•           Date dispensed 
 
• Instruc tions sta ting that the olapar ib tablets should be taken at approx imately t he 
same time each morni ng and evening 
 
4.2.11   
Storage  
 
All study drugs should be kept in a s ecure plac e under appropria te stora ge conditions. The 
inves tigationa l product label on the bottle and the Inves tigator Brochure specifies the 
appropriate storage. 
 
4.2.12  T reatment com plian ce 
 
The patient w ill be provided w ith a diar y in whic h each par ticipant must record date and time  
 
of each olaparib intake, reasons for any missed doses as well as any changes in dosing of stud y 
drug. Di aries w ill be provided to par ticipants on Day 1 of cycle 1 and Day 1 (+ /-2 day s) of ea ch 
50(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
 subsequent cycle. Di aries w ill be collected as sourc e documentation at t he end of each dosi ng 
cycles and at the EOT visit to document study drug admi nistration for eval uation of t reatment 
compliance. If t he participant does not return the diary, de legated staff must evaluat e and 
document dosing compliance. 
 
The patient should return all boxe s, bottle s, blist ers, and unused tablets of olapar ib at t he 
beginnin g of each new cycle (or at the end of each cyc le).  Any remaining or returned tablet s 
will be counted by t he Inves tigator or a designa ted per son from his/her team and recorded. 
 
If the patient does not bring the trea tment dispensed at the pre vious visit b ack, the numbe r of 
table ts taken w ill be e stimated b y the  Investigator usi ng the pa tient’ s diary and b y questioning 
the pa tient. The patient w ill need to return the study drug at the next visit.  The eCRF dr ug 
accountabilit y data entered by the study s ite per sonnel into the el ectronic data capture (EDC ) 
will be the data used by analy sis. 
 
Patients randomiz ed to receiving durvalumab w ill receive t reatment w ith durvalumab by stud y 
site staff at the study sites. Compliance w ill be a ssured by a dministra tion of the study trea tment 
under the supervision of Inves tigator or his/her designee. 
 
4.2.13  
Accountab ility 
 
Drug accountabilit y will be the responsibility of the Investigator and/or the phar macist.  The 
Inves tigator and/or t he phar macist of the center and/or a designated p erson from the study t eam 
must maintain an accur ate record of receipt of all study drug s, includi ng dates of receipt.  I n 
addition, accurat e records w ill be kept regarding when and how much study drug is di spensed 
and used by e ach pa tient in the study .  Reasons for departure from t he expected di spensing 
regimen must al so be recorded.  At the completi on of  the stu dy, all study drugs w ill be 
reconc iled and retained or destroyed accordin g to local procedu res and requirement s. 
Destruc tion of unused th erapeutic units w ill be pe rformed a ccording to s tandard moda lities f or 
that cla ss of product.  Destruc tion of  stud y drugs should occur f or product returned after dru g 
accounta bility or after expi ration date, or after the la st visit of the la st treated pa tient at the latest. 
51(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
4.3 Discont inuation of study treat ment 
 
Subjects must be w ithdraw n from study tr eatment for the following reasons: 
 
• At  thei r  own  request  or  at  the  request  of  thei r  legall y  acceptabl e  rep resenta tive 
(withdrawal of consent for t reatment). 
 
• At any time during stu dy treatment and w ithout giving reasons, a subj ect may dec line to 
participate further . The subj ect w ill not su ffer any disadvanta ge as a result. 
 
• If, in t he Inves tigator's opinion, continua tion of study trea tment would be harmful to the 
subject's we ll-being. 
 
• Severe  allergic  reactions,  such  a s  exfoliat e  erythroderma,  anaphylaxis,  or  cardio 
vascular collapse. 
 
• An y   othe r   potentia l   adver se   reaction   deeme d   sufficientl y  seri ous   t o   warrant 
discontinua tion of treatment by e ither the Inves tigator or a designated a ssociat e(s). 
 
• Substantial non-compliance w ith study procedure s. 
 
• Subj ects w ith a beta human chorionic gonadotropin te st consistent w ith pregnancy. 
Pregnancy w ill be reported along t he same timelines a s a serious adver se event (SA E) 
 
• Use of illicit drugs or other substances that may, in the opini on of  the Inves tigator or a 
designated a ssociate(s), have a r easonable chance of contributing  to toxicity or otherw ise 
confound the re sults. 
 
• Development of any inte rcurrent illness or s ituation that would, in the judgment of the 
Inves tigator, affect a ssessments of c linical status and stud y endpoints to a relevant 
degree. 
 
• Subj ects should disconti nue stu dy tr eatment if confirmed dis ease progression occur s. If 
the treating  physician fee ls that the subj ect will receive clinical benef it from continue d 
study trea tment de spite prog ression, the subje ct ma y remain on study drug after 
consulta tion w ith the stud y PI. Howe ver, the subj ect w ill be consider ed as havi ng 
progressive disease, a s per the RECIST 1.1 criteria 
 
• Subj ect lost to follow-up 
 
• The date of the la st dose of the s econd study drug is considered as the date of the end of 
the study trea tment 
 
• Permanent discontinua tion of a specific study drug should be decl ared by the s ite 
treating physicians 
52(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
In all cases, the reason for withdra wal fr om treatment must be recorded in the ca se report form 
(CRF) and in the subj ect’s medi cal 
records. 
 
4.4    Pro cedures for discont inuation of a subject from investigational product  
 
A subj ect whose trea tment is per manentl y discon tinued due to an adver se event or c linicall y 
signifi cant labo ratory value must be followe d up as per ins titutional practic e until resolution or 
stabiliz ation of the event, whichever comes first. 
 
An end of t reatment (EO T) visit should be conducted w ithin 30 days of the la st dose of the stud y 
drug or within 30 days of the decision to per manently discontinue the study drug. If the subj ect 
withdra ws from the study at a schedule d vis it, the EOT a ssessment can be performed on that 
day. (See sec tion 4.5.3 for visit deta ils) 
 
Any subj ect who has not prog ressed at the time of discontinua tion of study tr eatment w ill 
continue to have tumor a ssessments perf ormed ever y 8 weeks until dis ease prog ression, 
initia tion of subsequent anticancer th erapies or death, whichever comes first. 
 
Upon t reatment discontinua tion, subj ects w ill be fo llowe d every 2 months f or survival.  
Completion of the survival follow -up period will occur once the last subject in the 
Extension period discontinues study treatment, or the Extension period reaches one 
year of duration, whichever comes first.   
 
4.5    Collect ion of st udy variabl es 
 
The site Inves tigator w ill ensure the a ccuracy, completene ss, and time liness of the data recorded 
and of the provision of ans wers to data quer ies according to the C linical Study Agr eement. Data 
will be entered into t he electronic case report form (eCRF) of a web-based data management 
system. Site personnel will be t rained and responsible for ent ering data spe cified in the protocol 
into t he eCRF accordin g to the e CRF Instruc tions. Site personnel w ill provide their site local 
labora tory lab normal range values duri ng the data man agement system set-up. When a ll data 
has been ent ered, reviewed, and sourc e data ver ification completed; the site PI w ill be notified 
to sign the e CRF electroni cally. 
 
4.5.1    
During olaparib or olaparib and durvalu mab main tenance 
 
Cycle 1 Day 
1 
 
The following a ssessments will be done prior to administra tion of maintenance tr eatment: 
 
•       Physical exa mination 
 
•       ECOG perf ormance status 
 
•       Vital signs (weight, temp erature, blood pre ssure, re spiration and pulse) 
 
•       Hematology 
 
•       Blood che mistry 
 
53(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
 •       Liver func tion tests 
 • Thyroid func tion tests for combina tion arm only (thyroid s timula ting hormone (TS H), 
free triiodothyronine (T3), and free thyroxine ( T4))  
 
• El ectrolyt es 
 
• Corre lative blood sample s for t ranslational studies 
 
• A ssess adver se events (AE) 
 
• R ecord concomitant medi cation 
 
• Di spense olaparib or ola parib and administer durvalumab 
 
See Appendix G for addi tional labora tory requirements for Korean s ites onl y. 
 
4.5.2 Subs equent vi sits 
 
Subsequent vis its w ith study doctor should occur once every 28 days +/- 3 days for Cycle 2 
onwar d. Mo re frequent visits  are per mitted if clinically indicated.  
While the  followi ng asse ssment s will continue to be perf ormed, they will only be done for 
clinical purposes. These data will no longer be entered into the study databa se: 
 
• Phy sical exa mination 
 
• ECOG perf ormance stat us 
 
• V ital signs (weight, temp erature, blood pre ssure, re spiration, pulse) 
 
• Hematology and Che mistry per tables 6 and 7 that follow: 
 
 
Tabl e 6. Hematology Laboratory Tests  
 
 
 
Basophils Mean corpuscular volume 
 
Eosinophils Monocytes 
Hemat ocrit Neutrophils 
Hemoglobin Platelet count 
Lymphocytes Red blood cell count 
Mean corpuscular hem oglobin Total white cell count 
Mean corpuscular hem oglobin 
concentra tion 
  
  
 
54(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
  
Tabl e 7. C linical chemis try (Serum o r Plasm a) Laboratory Tests  
 
Albumin  Glucose 
Alanine a minot ransferase Thyroid stimula ting hormone (TSH) , free 
triiodothyronine (T3), and fre e thyroxine ( T4)) 
(combina tion arm only) 
Magnesium 
Aspartate a minot ransfera se Potassium 
Bicarbonate Sodium 
Calcium Total bilirubina 
Chloride Total prote in 
Creatinine  Urea or blood urea nitr ogen, depending on loca l 
practice 
a  If Total bilirub in is ≥2xULN (and n o eviden ce of Gilbert’s s yndrome) then fr actionate into dir ect and indir ect 
bilirub in 
 
See Appendix G for addi tional labora tory requirements for Korean s ites only. 
 
4.5.3 End-of-s tudy visit 
 
When it ha s been det ermined that a subj ect should be removed from trea tment, she w ill be 
asked to re turn for a tr eatment t ermina tion vis it, which should pref erably occur w ithin 30 da ys 
after her la st administra tion of stu dy drug. Wherever possible, this visit sh ould also be 
under taken by subje cts who w ithdre w from the st udy premature ly. A ll subje cts w ill be 
followe d for a minimum of 30 days after the la st dose of olapar ib/durvalumab. 
 
If a subj ect is removed from the study due to drug- related adver se event s, the subj ect w ill be 
followe d until resolution of any drug- related AE o ccurring during the study or w ithin 30 da ys 
of the la st olapar ib/durv alumab dose, or for 30 days, whichever is longer. I n the pre sence of 
toxic effects,  follow-up visits  will be required every four weeks until a ll study-related 
toxicities have resolved to base line (or <Grade 1 per CTCAE), have stabilize d or are deem ed 
irreversible. 
 
The following a ssessments will be made during the end of study vis it: 
 
• Physi cal exa mina tion (including ora l/tympanic t emperature and body weight) 
 
• ECOG perf ormance stat us 
 
• Vital signs (systo lic and diastolic blood pre ssure, pulse rate). 
55(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
• Clini cal labora tory profile (hematol ogy, biochemi stry and liver func tion test) per tabl es 
6 and 7 
 
• Radiologi cal disea se status a ssessment at Investigator’s dis cretion 
 
• Serious Adver se Events recording 
 
The only data to be entered into the eCRF from this visit will be the End of Treatment reason, 
radiological disease status assessment (if applicable) , and Serious Adverse Event (if applicable).  
 
  
4.6 Biological sampling pro cedures 
 
 
The volume of blood that w ill be draw n from each subj ect in this study is as follows: 
 
Tabl e 8: Volu me of blood to be drawn from each s ubject  
 
 
 
Assessment Sample 
volume (mL)  Frequency  of 
Sampli ng To tal volume  
(mL)  
 
Safety Clinical 
chemistry  
3 Once at the start o f 
each cycle  
18 (for 6 cycles) 
 
Hematology 3 Once at the start o f 
each cycle 
 
Bioma rker 30 At predefined tim e 
points  
18 (for 6 cycles) 
 
 
120 (4 time 
points) 
56(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
 Total 36 156 
 
 
  
 
4.6.1    Handl ing, storage and des truction of biological samples 
 
Serial blood samples w ill be collected from a ll patients. Please refer to Appendix A for schedul e 
of assessment for sampli ng time points and table 9 for blood volume to be collected. All blood 
samples w ill be collected by e ither direct venipuncture or an indwe lling central venous cathet er. 
Complete instruc tions f or blood s ample processing, handling and shipment will be provided in 
the Labora tory Manual. 
 
4.6.2    Bi omar ker sam ples 
 
The specific des cription of collection, handling  and shipment of the se samples is des cribed in a 
separate Corre lative Science Lab Manual. 
 
Related to biom arker blood sa mple  collection, specifically, the sites will collect blood at visits 
C1D1, D1 after each staging cycle (C3D1,  C5D1, C 7D1 etc), and EO T; please refer to the 
Schedule of A ssessments (Appendix A) for furthe r detail. 
 
While t he goal of t he biom arker a ssessments is to provide suppor tive data for the c linical study , 
there may be circums tances when a decision is made to stop collection or not perf orm or  
discon tinue an analysis due to e ither practi cal or st rategic reason (e.g. inadequate sampl e 
number , issues w ith qua lity of sample, i ssues w ith a ssays etc.). Depending on the results 
obtained during the study, sample coll ection and/or analysis may be omitted at the dis cretion of 
the study chair. If a de cision is made by study chairs to stop collection  of blood sample s, 
notifi cation w ill be provided to every investigator in wr iting. 
 
4.6.3    Wit hdrawal of informed consent for donate d biomarker sam ples 
 
As collection of the biom arker samples is  an integral par t of the study, if the subj ect w ithdraws 
consent from the study, the stud y team w ill continue to retain and use all research results that 
have alr eady been colle cted for t he study eva luation. All biologi cal samples that have alr eady 
been colle cted may be retained and analysed at a late r date or as requi red by loca l regula tions. 
If a pa tient w ithdraw s consent for the study, the i nvestigator must make ever y effort t o det ermine  
the pr imary reason for this decision and  record this informa tion. Subj ects may deci de to stop 
biom arker colle ction but continue on study. This does not cons titute w ithdrawal of conse nt 
for the entire st udy. 
 
4.7    Follow-up procedures  
 
30-day saf ety follow-up 
 
All subj ects w ill have s afety evalua tions for 30 days following the la st dose of the stud y 
treatment. A Es will be a ssessed until 30 days following the la st dose of olapar ib and/ or 
durvalumab. All concom itant medi cations given to a pa tient as a result of an S AE exper ienced 
during this per iod w ill be recorded. All cancer medi cations /therapies given to a subj ect ≤30 da ys 
after the la st dose of olap arib/durvalumab must be recorded. Subj ects lost to follow-up shoul d 
be recorded a s such. 
 
57(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
 Disease progression foll ow-up 
 
Any subj ect who has not prog ressed at the time of discontinua tion of study tr eatment w ill 
continue to have tumor a ssessments perf ormed ever y 8 weeks (+/- 7 days) until dis ease 
progression, initia tion of subsequent antican cer th erapies or d eath, whichever comes first. 
 
Survival fo llow- up 
 
Upon comple tion of the 30-day safety follow-up or dis ease prog ression fo llow-up, all subj ects 
except those who died, w ithdre w consent or w ere lost to follow-up w ill be followe d for su rviva l 
every 8 weeks (+/- 7 day s) until death. Completion of the survival follow -up period will occur 
once the last subject in the Extension period discontinues study treatment, or the Extension 
period reaches one year of duration, whichever comes first.   
 
4.8   
 Efficacy  
 
The first disease evalua tion for subj ects followi ng start of olapar ib or olapar ib in combina tion 
with durvalumab w ill occur at w eek 8 +/- 7 day s. Subsequent to the first tumor evalua tion, 
disease status and tumor response w ill be asse ssed per RECIST using stand ard CT/MRI s cans 
in eight-week int ervals (+/- 7 day s) unti l disease prog ression as def ined by RECIST 1.1 or as 
clinically indi cated. 
 
For subj ects who disconti nue any of t he study dru g due  to toxicity in t he absence of confirme d 
objective p rogression, obj ective tumor a ssessments should be continued every 8 w eeks (+/- 7 
days) f or until confirmed obj ective dis ease progre ssion. 
 
If study s ubj ect is on durvalumab, dis ease prog ression requires confirma tion. The confirmator y 
scan should occ ur preferabl y at the next schedule d visit and no ear lier than 4 weeks after the 
initial a ssessment of prog ressive disea se (PD) in the absence of clini cally signif icant 
deterioration. T reatment w ith olapar ib and durvalumab w ill continue be tween the initia l 
assessme nt of  prog ression and confirma tion for prog ression. Subj ects w ith rapid tum or 
progression or with symptoma tic pr ogression that requires urgent med ical intervention (eg , 
ce
ntral nervous system metastasis, respiratory failure due to tumor compre ssion, spinal cor d 
compre ssion) w ill not be e ligible to continue to receive study drug. 
 
4.8.1    Efficacy ou tcome measures 
 
Only response evaluation per RECIST will be entered into e CRF  for the Extension period.  
 
The primary e fficacy outcome m easure is a s follow s: 
 
PFS,  def ined as the time from randomiz ation to the fir st occur rence of disea se progre ssion (as 
determine d using RECIST v1.1 criteria and a ssessed by the Investigator) or death from an y cause 
on study. Death on study is d efined as d eath from  any cause w ithin 30 days of t he last dose  of 
study trea tment reg imen. Tumor prog ression w ill be a ssessed locally at each s ite by t he 
inves tigators a ccordi ng to RECIST 1.1.   No independent review of tumor prog ression i s planned. 
PFS w ith disease progression det ermined by iRECIS T will  also be exa mined in explora tory data 
analysis for the combina tion arm. The secondary efficacy outcome measures in all subj ects are 
as follow s: 
 
• OS (overall surviva l) defined as the time from randomiza tion until death from  any cause. 
58(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
• ORR (overall response rate) def ined as the subj ects achieving Complete Response or 
Partial Response as def ined by RECIST 1.1. 
 
• CBR (clinical ben efit rate) defined as subje cts achieving Complete Re sponse, P artial 
Response or Stable disea se ≥ 24 w eeks 
 
Methods of meas urement 
 
The following definitions  and criteria (from RECIST 1.1) should be used for the base line 
evalua tions of  exis ting dis ease and for the ongoing evalua tion of  tumor response s. All 
measurements should be taken and r ecorded in metric nota tion, using a ruler or calliper s. In the 
case of skin lesions, documenta tion by col or photog raphy and a measurement w ith a rule r to 
estima te the size of the lesion is recommended. 
 
• Measurabl e disease - the pre sence of at l east one m easurable lesion. 
 
• Measurabl e lesions – non-lymph node lesions that can be accurately m easured in at 
least one dimension w ith LD 20 mm using conventional t echniques or 10 mm  with spiral 
CT s can, or 15mm for lymph nodes w ith spiral CT. 
 
• Non-measurabl e lesions - all other lesions ie, bone lesions, asc ites, pleur al/pericardial 
effusion, includi ng lesions that do not m eet the m easureable criteria above.  
 
• Conventional CT should be perf ormed w ith cuts of 10 mm or le ss in slice thickne ss 
conti guously. Spi ral CT should be perf ormed using a 5-mm conti guous reconstruc tion 
algor ithm.  
 
All imagi ng methods should be perf ormed a ccording to institutional standards w ith each subj ect 
having consistency of methods beginning from base line through the course of the study. 
 
Tabl e 9: Re spon se criteria 
 
Evaluation of target lesions 
Complete 
Respons e (CR): Disappearance of all target lesions 
Partial Response 
(PR): At least 30% decrease in the sum of the LD of target lesions, taking as reference the 
baseline sum LD 
Progressive 
Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the 
nadir (smallest sum ) LD r ecorded  since the tr eatment s tarted or the a ppearan ce of one o r 
more new lesions 
Stable Disease 
(SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, 
taking as referen ce the sm allest sum LD sin ce the tr eatment s tarted 
Evaluation of non-target lesions 
Complete 
Respons e (CR): Disappearance of all target lesions 
Stable Disease 
(SD) Persistence of one or more non-target lesion(s) 
59(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
 Progressive 
Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non- 
target lesions 
 
 
Evalu ation of Be st Over all Respon se 
 
The best overall response is the be st response recorded from the s tart of the t reatment until 
disease progre ssion and is det ermined as per Table 10 below. 
60(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
Tabl e 10: De finition of be st overall respon se as per RECIST criteria  
 
Targ et lesions Non-Targ et lesions  Evaluation of New lesions Overall response  
CR CR No CR 
CR SD No PR 
PR Non- PD No PR 
SD Non- PD No SD 
PD Any Yes or No PD 
Any PD Yes or No PD 
Any Any Yes PD 
 
 
To be conside red a re sponse, CR or PR m ust persist for a m inimum of 4 w eeks. If, at the time 
of tumor response evaluation, e ither a PR or CR is obs erved, the same radiographic study should 
be repeated 4 weeks later for confirma tion of response. After this confirma tory study, subj ects 
should return to the schedule of evalua tions as previously described. 
 
5     SAFETY  
 
The Principal Investigator is responsible for e nsuring that all st aff involved in the study i s 
familiar w ith the content of this  section. 
 
5.1     Definition of adv erse events  
 
An adver se event (AE) is the developme nt of  an undesirable medical condition or t he 
deterioration of  a pre -exis ting medi cal condition following or during exposure to a 
pharmaceutical product, whether or not considered causally related to the product. An 
undesi rable medic al cond ition can be a symptom (eg, naus ea, che st pain), sign (eg, tachyc ardia, 
enlarged liver) or the abnormal results of an inves tigation (eg, labora tory findings, 
electroc ardiogram). In clini cal studie s, an AE can include an undesi rable medi cal condi tion 
o
ccurring at any time even if no study trea tment has been administered. 
 
The term AE is used to include both s erious and non-s erious A Es. The Common Terminology 
Criteria for Adv erse Events (CTCA E) version 4.03 w ill be used to re port A Es for this study. 
 
5.2    Definitions of s erious adverse  event  
 
A serious adver se event is an AE occu rring during any study pha se that fulf ils one or more of 
the following cr iteria: 
 
•           Results in death  not re lated to breast  cancer dis ease prog ression 
 
•           Is immediately life-threateni ng 
 
•           Requi res in-pa tient hospital ization or prolonga tion of exis ting hospital ization 
 
•           Results in persistent or si gnificant disa bility or incapacity 
61(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
•           Is a congenital abnormal ity or birth de fect 
 
• Is an important medi cal event that may jeopar dize the subj ect or may requir e 
medi cal int ervention to p revent one of the outcomes listed above. 
 
The causa lity of SAEs (their relationship to all study trea tment/procedure s) will be a ssessed 
by the Inves tigator(s)  and documented or repor ted on the SAE e CRF page. 
 
5.3    Definition of adver se events of sp ecial interest (AESI) 
 
An adver se event of  special interest (AESI) is one of scientif ic and medi cal interest specific to 
under standin g of the Inves tigational Product and may require close monitori ng and rapid 
communi cation by the inves tigator to the sponsor. An AESI may be serious or non-serious. The 
rapid reporting of AESIs a llows ongoi ng surveillanc e of these events in order to char acterize 
and under stand them in a ssociation w ith the use of this inves tigational product. 
 
AESIs for durvalumab include but are not limited to events w ith a potential inflammator y or 
immun e-mediated m echani sm and which may require more frequent monitori ng and/ or 
interventions such as st eroids, immunosuppre ssants and/or hormone replacement therapy . These 
AESIs are being closely monitore d in c linical studies wi th durvalumab monotherapy and 
combina tion therapy. An immune- related adver se event (irA E) is defined as an adver se eve nt 
that is a ssociated w ith drug exposure and is consistent wi th an immune-mediated m echani sm of 
ac
tion and where there is no c lear alternate aetiology. Serologic, immunologic, and histologi c 
(biopsy) data, as appropriate , shoul d be used to support an i rAE diagnosi s. Appropriat e effort s 
should be made to rule out neoplas tic, inf ectious, metabolic, toxin, or othe r etiologic cause s of 
the irAE. 
 
O
nly AESIs meeting serious criteria will be reported during the Extension period.  
 
 
If the Investigator has any questions i n regards to an adverse  event (A E) be ing an 
irAE, the Investigator shoul d promptly contac t the St udy Chair. 
 
Criteria for Hy’s Law (FDA G uidance 2009)  
 
• The d rug causes hepatoce llular injury, generally shown b y a highe r incidence of 3-fol d 
or greater eleva tions above the ULN of ALT or  AST than the (non-hepatotoxic) contr ol 
drug or placebo 
 
• Am ong   trial   subj ects   showi ng   suc h   aminot ransferase   eleva tions,  ofte n   w ith 
aminotransferases much gr eater than 3 x ULN, one or more al so show eleva tion of s erum 
total bilirubin to >2 x ULN, without initial findings of chole stasis (elevated s erum 
alkaline phosphatase). 
 
• No other reason can be found to explain the combina tion of increased a minot ransferases 
and total bilirubin, su ch as vi ral hepa titis A, B, or C; pre -exis ting or acute liver dis ease; 
or another dru g capable of causing the observed injury. 
 
5.4    Recor ding of adverse  events  
 
For the Extension period, only SAEs will be reported in eCRFs. Non -serious AEs will be 
62(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
 managed according to the site’s clinical practice and the toxicity management guidelines set 
forth in this protocol, but will not be reported in eCRFs . 
Informa tion about all SA Es, whether volunt eered by t he subj ect, discove red by Investigat or 
questioning, or det ected through physi cal exa mination, labora tory test, or other m eans, w ill be 
collected and recorded a nd followe d as appropr iate. 
 
All SAEs,  whethe r or not deeme d drug-related, m ust be reported w ithin IBM- CD (eCOS) 
by the site Inve stigator or qua lified de signee w ithin 1 busine ss day of first becoming 
aware of the event. 
 
Ques tions about SAE repor ting can be re ferred to D CRI Safety Surve illance at 1- 919- 
668-8624, or at 1-866-668-7799 wit hin Nort h America. 
 
If the IBM-CD sy stem is temporar ily unavailable, the event, including the Inves tigator- 
determined causa lity to study drug, should be reported via a paper back-up SAE form t o 
DCRI S afety Surve illance. Upon return of the av ailability of IBM-CD system, the SA E 
informa tion must be ente red into IBM-CD. 
 
The following v ariables w ill be collected in the eCRF  
during the Extension period for each SA E: 
 
•           S AE (ver batim per CTCA E) 
 
•           The date when the SAE st arted and stopped 
 
•           Changes in NCI CTCAE grade and the max imum C TC grade attained  
 
  
•           Inves tigator causa lity ra ting against the Investigational Product (yes or no) 
/combina tion dr ug (yes/no) 
 
•           Action taken w ith reg ard to inves tigational product /combina tion agent 
 
•           Outcome 
 
 
•           Date AE met cr iteria for s erious AE 
 
• R eason AE is def ined as s erious (fatal or life th reatening, re sults in persistent or 
significant disa bility /incapacity, constitutes a congenital anomaly/bir th defect,  is 
medi cally significant, requi res inpa tient hospita lization or prolonga tion of ex isting 
hospita lization). 
 
•           Date of hospita lization 
 
•           Date of discharge 
 
•           Probable cause of death  
 
•           Date of death 
 
63(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
 •           Autopsy pe rformed 
 
•           Description of AE 
 
•           Causa lity assessment in rela tion to St udy procedur e(s) 
 
•           Causa lity a ssessment in relation to other medi cation 
 
•           Causa lity a ssessment in relation to additional study drug 
 
It is important to dis tingui sh between serious and sever e AEs. Sever ity is a m easure of intensity, 
wher eas s eriousne ss is defined by the criteria in Section 5.2. An AE of severe intensity n eed not 
necessaril y be consid ered serious. For example, nausea that per sists for several hours may be 
considered sev ere nausea, but not a SA E. On the other hand, a stroke that results in onl y a 
limited degree of disability may be considered a mild stroke but would be a SA E. 
 
5.4.1    
Time period for collect ion of adverse  events and s erious adverse  events  
 
All SAEs w ill be collected during the extension period through 30 da ys after the la st dose of 
either drug or until the initia tion of an a lternative anticancer th erapy. Pl ease refer to the 
Schedule of A ssessments in Appendix A. 
 
5.5    Follow-up of unre solved serious adver se events  
 
All SA Es should be treated appropriately. Such tr eatment ma y include changes in study dru g 
treatment, includin g pos sible int erruption or discontinua tion, s tarting or stopping concom itant 
treatment s, changes in the frequency or nature of a ssessment s, hospita lization, or any othe r 
medi cally required inte rvention. Once an SAE is det ected, it should be followe d until its 
resolution, and a ssessme nt should be made at each visit (or more frequentl y, if ne cessary) of 
any changes in sever ity, the suspected relationship to the stu dy drug, the int erventions required 
to treat it, and the outcome. 
 
5.6   
 Adverse  events b ased on signs and symptoms  
 
When collecting SA Es, the recording of dia gnoses is pref erred (when possible) to r ecording a list 
of signs and symptom s. Howe ver, if a dia gnosis is known and ther e are other signs or symptom s 
that are not generally part of the diagnosi s, the diagnosis and each sign or sy mptom w ill be 
recorded sepa rately. 
 
5.7    Adverse  events b ased on exam inations and tests 
 
Deterioration as compared to base line in protocol-mandated labo ratory value s, for vital signs 
should only be reported if they fulf il any of the SAE criteria or are the r eason for discontinua tion 
of trea tment w ith the inves tigational product.  
 
If deter ioration in  a labora tory value/vital sign is associated w ith clinica l signs and symptoms, 
the sign or symptom w ill be re ported as the event   and the a ssociated labora tory result/vital sign 
will be  considered as add itiona l informa tion. Where ver poss ible the reporting Inves tigator uses 
the clinical,  rather than the labora tory term (eg, ane mia ver sus low hemoglobin value) .  
 
Deterioration of a labora tory value, which is unequivocall y due  to dis ease prog ression, should 
not be reported a s an S AE 
 
64(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
Cases wher e a subj ect shows an AST or ALT ≥3xULN and total bilirubin ≥2 xULN ma y need 
to be reported a s SA Es, please refer to S ection 5.3 (AESI def inition) f or further instruc tions. 
 
5.8    Disease progressi on 
 
Disease progre ssion can be considered as a worsening of a subj ect’s condition a ttributabl e to 
the dis ease for which the inves tigational product is being studied. It may be an inc rease in the 
sever ity of the disea se under study and/or inc reases in the symptoms of the dis ease. SA Es due 
to prog ression w ill be reported and cla ssified as unr elated to t reatment. 
 
5.9    New can cers 
 
The development of a new pr imary cancer should be reg arded as an SAE since this event  will 
generally meet at least one of  the s erious criteria (see S ection 5.2). New pr imary cancers are 
those that are not the  primary reason for the a dministra tion of  the study treatment and have 
developed after the inclusion of  the subj ect into the study. These do not include metastase s of 
the original canc er. Symptoms of meta stasis or the meta stasis itself should not be reported as 
an A E/SAE, as they are consid ered to be disea se progre ssion. 
 
5.10  Lack of efficacy  
 
When ther e is det erioration in the condition for which the study tr eatment( s) is bei ng used, 
mTNBC, there may be uncertainty as to whether this is l ack of efficacy or an A E. In such cases, 
unless the Sponsor or the reporting physician consider s that the study treatment contributed t o 
the det erioration of  the condition, or  local regulations sta te to the cont rary, the det erioration 
should be considered to be a l ack of efficacy and not an A E. 
 
5.11  Deaths 
 
All deaths that occur during t he study, or within the protocol-defined 30-day post-stud y 
follow-up per iod after the administ ration of  the last dose of study tr eatment, must be reporte d 
as follow s: 
 
• Death that is clearly the result of dis ease prog ression should be documented in t he 
eCRF but should not be reported as an SA E. 
 
• Wher e death is not due (or not cl early due) to progre ssion of t he disease under study , 
the main or primary  event causing the death must be documented in the e CRF as a 
SAE w ithin 1 business day (see S ection 5.2 for further details). The report should 
contai n a comment reg arding the co-involvement of prog ression of dis ease, if 
appropriate, and should a ssign main and contributory causes of de ath. 
 
• Deaths w ith an unknown cause should alway s be reported as a SA E. A post morte m 
maybe helpful in the a ssessment of the cause of death, and if perf ormed a c opy of the 
post-mortem results should be included w ithin the e CRF. 
 
5.12  Other events requi ring report ing 
 
5.12.1  Pregnan cy 
 
If a pa tient b ecome s pregnant duri ng the course of the study, the IPs should be disconti nued 
immediately. 
 
65(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
 Pregnancy itself is not regarded as an AE unle ss there is a susp icion that the IP under study ma y 
have int erfered w ith the effectivene ss of a cont raceptive medi cation. Congenital abnorma lities 
or birth defects and spontaneous miscarriages should be reported and handle d as SA Es. Elective 
abortions w ithout complications should not be handled as A Es. The outcome of all pregnanci es 
(spontaneous miscarriage, el ective  termina tion, ectopic pregnancy, normal birth, or congenita l 
abnorma lity) should be followe d up and documented even if the pa tient was d iscontinued from 
the study. 
 
If any p
regnancy occurs in the cour se of the study, then the Investigat or or other s ite personne l 
should inform the sponsor or their designated representa tives within 1 busine ss day, ie, 
immediately, but no later than 1 bus iness day of when he or she becomes aware of it. 
 
The same timelines apply when outcome inform ation is ava ilable. 
 
 
5.12.2  Re porting of s erious adverse  events  
 
SAEs are reported w ith the e CRF database within 1 busine ss da y of the inves tigator’s knowle dge 
of the event. 
 
*
 The inve stigative site must a lso indi cate, the causality  of events in relation  to all study 
medications and if the SAE is related to disease progre ssion, as det ermined by the site Principal 
Inves tigator. 
 
 
5.12.3 Translational s tudy 
 
Biopsies and ti ssue sp ecim en 
 
At time of  enrollme nt, all archiva l or fresh tissue obt ained w ill be banke d. This  will be a 
requirement for par ticipation in the study. Wher e possible, forma lin-fixed paraffin embedded 
(FFP E) b locks are pref erred. If blocks are unava ilable, thirty unstained and unbaked 5- μm slides 
from each subje ct (minimum of 10 s lides for pre-trea tment biopsy/a rchival tissue  require d) 
should be processed as close to batch shipme nt date as possible. Post-t reatme nt biopsy is 
encouraged but optional. All tissue  will be banked at the site until the batch shipment date near 
full enrolme nt of  the trial. E ach sample w ill be labe lled w ith Subj ect ID code and the required 
number of s lides retained / shipped to the relevant research labora to ries .   All blood, ti ssue 
samples and buc cal swabs w ill be proce ssed centrally b y the Duke BioRepos itory & Precision 
Patholog y Cente r (BRPC). Shippi ng back to the Duke BioRepos itory & Precision Patholog y 
Cente r (BRPC ) will be a rranged and communi cated to  the sites nearing the end of enrollment . 
Please see lab manual for further deta ils. 
 
All study subj ects w ill have a buccal s wab for ger mline DNA collec ted during s creening; the se 
will banked at study s ites until t he end of the study. 
 
Imm unoh istochemical H RD assay  
 
Banked tum or sample s will be prof iled based on protein expre ssion using multiplexe d 
microscopy. The multipl exing a bility of the Opal- Vectra system w ill be used to study diff erent 
antibody combina tions relevant to homologous recombina tion for all samples obtained in thi s 
66(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
 study. 
 
Whole exome se quenc ing (WES ) 
 
DNA sample s will be obtained from the tumor s amples and from the buccal DNA s wabs that 
will be obtaine d during s creening. PCR-based exon sequenci ng will be performed usin g standar d 
technique s. Gene tic variants w ill be charact erized as missense, nonsense, and frameshift, and 
then w ill be narrowe d by retaining only somatic rare variants and homozy gous mut ations. Wa ld 
testing  will initiall y be used to def ine relationships betw een gene a lterations and response to 
therapy. 
 
We al so have a very large set of prof iled pr imary and metasta tic TNBC samples (both 
carbopla tin sensitive and inse nsitiv e) that will serve as a compa rator set f or the samples in this 
proposal (Bl ackwe ll, SAB CS, 2013). We w ill be able to use this establi shed and we ll- 
characterized set for quality control and gene mutation compar ison. 
 
Imm un
e prof iling  
 
Immune prof iling will be done using stand ard immunoh istoche mistry techn iques. The followin g 
immune m arkers will be stained and quantitated using an exper ienced brea st pathologi st who 
will quantitate staining in tumor and in the stroma. The following m arkers will be a ssessed 
initially: 
 
1.   Quantita tive TILs using H and E stained s lide21 
 
2.   C D4 
 
3.   C D8 
 
4.   FoxP3 ( SP97) 
 
5.   Anti PDL-1 (E1L3N) 
 
Modifi cations to the immune m arkers may be made depending on emerging evidence.  
 
 
6    ETHI CAL AND REGULATORY REQUIREMENTS  
 
6.1    Ethical conduct of the st udy 
 
This trial w ill be conducted in compliance w ith this protocol, Good C linica l Practice guide lines 
(eg, ICH E6: Good Clini cal P ractice or Singapore Guide line for Good Clini cal Practic e 
[SGGCP]), and applicable na tional and local regulatory requirement s. 
 
The site Pr incipal Investigat or shall ensure that per sonnel involved in the conduct of thi s stud y 
are qua lified by education, t raining, and exper ience to pe rform their respective ta sks. The site 
Principal Inve stigator has ultima te responsibility for trial conduct at the site. 
 
The study will be pe rformed in accordanc e with ethical pr inciples that have their orig in in the 
Declara tion of Helsinki and are consistent w ith ICH/Good C linical Prac tice, and applic able 
regulatory requi rement s. 
 
67(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
6.2    Subject data prote ction  
 
Subjects w ill be a ssigned unique code numbers and w ill not be identif ied by name. Subj ect 
confidentia lity is held strictly in trust by the par ticipating Investigator s, their st aff, the 
sponsor(s), and their agent s. This confidentia lity extends to gene tic and biolog ical sample tests, 
in addition to the c linical informa tion relating to participating subj ects. 
 
The sponsor w ill not provide individua l genoty pe results to subj ects, any insura nce company, 
any employer, their fa mily member s, general physician or any other th ird party, unle ss required 
to do so by l aw. 
 
Extra precautions are taken to pre serve confidentia lity and p revent gene tic data being linked t o 
the identity of the subje ct. In ex ceptional circumstances,  howe ver, certain s tudy st aff might se e 
both the gene tic data and the per sonal identifi ers of a subj ect. For example, in the case of a 
medi cal emergency, the medi cal monitor or an Inves tigator might know a subj ect’s identity and 
also have ac cess to his or her gene tic data. Also, Regulator y author ities may require access to 
the relevant f iles, though the subj ec t’s medical informa tion and the gene tic files would remain 
physi cally sep arate. 
 
Th
e study protocol, documenta tion, data, and all other informa tion generated w ill be held i n 
strict confiden ce. No informa tion conc erning t he study or the data w ill be released to an y 
unauthor ized third par ty without prior written approval of the sponsor. 
 
6.3    Et hics and regul atory review 
 
Before study initiation, the Inves tigator must have written and dated approva l/favorable opinion 
from the IRB/I EC for the protocol, consent form, subj ect recruitment mat erials/process (eg, 
adver tisements), and any other wr itten informa tion to be provided to prosp ective subje cts. The 
Inves tigator should al so provide the IRB/I EC with a copy of t he produc t labelling informa tion 
to be provided to prospe ctive subj ects, along w ith any update s. 
 
Th
e Investigator should provide the IRB/I EC with reports, update s, and othe r informa tion (eg, 
expedited s afety reports, amendment s, and a dministra tive le tters) according to local and na tional 
regulatory requirements or ins titution procedure s. 
 
6.4    Informed consent  
 
Inves tigators must ensure that subje cts are cl early and full y informed about the purpose , 
potential r isks, and other cr itical issues reg arding this  clinica l stu dy for which the y are 
volunt eering to p articipate. 
 
Before any study procedure s are performed, poten tial subj ects w ill have t he outline  of the stud y 
described to them, and they w ill be given a written informed consent document to read. If the y 
consent to par ticipat e in the study, they w ill indi cate that consent by signing and da ting the 
informed consent document in the pre sence of study personnel. Any subj ect who signs th e 
consent form w ill be considered a “scr eened” subj ect. 
 
6.5    Changes to the protocol and informed consent form  
 
Should amendment s to the protocol and/or informed consent docume nt be required, t he 
amendments w ill be written by the sponsor and provided to the Inves tigator for submission to 
68(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
 their IRB/IEC. 
 
6.6    Protocol deviations  
 
Protocol deviations (noncomplianc e with the clini cal trial pr otocol, Good C linical Practic e 
(GCP), Manual of Procedure s or requireme nts) will be noted in Site Monitoring reports. Of no te, 
noncomplianc e may be e ither on the part of t he participant, the s ite Investigator, or t he stu dy 
site staff. Sites are expected to develop and implement correc tive actions promptly. 
 
It is the responsibility of the s ite to use conti nuous vig ilance to identif y and report devia tions. 
All devia tions must be promptly reported to the sponsor or their designee. 
 
All devia tions from the protocol must be addre ssed in study subje ct sourc e document s. Protocol 
devia tions must be reported to the local IRB/I EC per local guide lines. The site PI/study staff is 
responsible for knowing and adher ing to thei r IRB/I EC requi rement s. 
 
6.7    P ublication policy  
 
Dissemination of pre limin ary informa tion can adv ersely af fect the objec tivity of study data. F or 
this reason, Inves tigators w ill not be allowe d to perform subset analyses at any point before th e 
conclusion of the study, and any data, othe r than s afety data, cannot be used for publication or 
repo r ting outside of this study until the study is completed or discontinued by t he 
sponsor /investigator. 
 
 
7    STATISTI CAL METHOD S AND SAMP LE SIZE DETERMI NATION  
 
7.1    Statistical analyses and d etermination of sa mple size 
 
Based upon current stand ard of care,30 the median PFS (mPFS ) in this p opula tion is estimate d 
to be approximately 2 months, and a clinically relevant improvement w ith either of the proposed 
maintenanc e treatm ents would be to an mPFS of 4 months. In both arms of the study, it i s 
proposed to te st a null hypothesis of an mPFS of 2 months against an a lternative hypothesis of 
an mPFS of 4 months. To test this hypothesi s, assuming an exponential PFS distribution, use of 
an exponential MLE test, a two-sided signifi cance lev el of 5% and a power of 90%, 25 subj ects 
are required per arm. To allow for a drop-out rate of approx imatel y 20%, the sample s ize per 
arm will be inflated to 30 subj ects, for a total of 60 subj ects. 
 
Co
mpar ison bet ween the two t reatment arms w ill be perf ormed as an explora tory analysi s. 
 
The number of subj ects that will agree to participate in the gene tic research is unknown. It is 
therefore not  possible to establish  whe ther sufficient da ta will be c ollected to allow a forma l 
statistica l evaluation or whe ther only des criptive sta tistics will be gene rated. A statistical 
analy sis plan w ill be pre pared wh ere appropriat e. 
 
7.2    Saf ety data review commit tee 
 
Accr uing vital status, progre ssion, and safety data w ill be reviewed by t he committee compr ising 
the Dora Study Chair, Study Co-Chair and Correla tive Science Chair; one of t he Study Chair s 
will serve as the bi-monthly c ommittee m eeting  leader.  The DCRI statistician will s erve as t he 
meeting secretar y and wi ll provide agr eed-upon statistical reports in advance of the committee 
meetin g. The Safety Data Review Committ ee’s primary goal is to deter mine  if there is a clea r 
69(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
 early difference betw een the Arms A and B in t erms of safety, efficacy, or ri sk-benef it. The 
Safety Data Revie w C ommitte e may invite  opinions from the study site inve stigators, 
intermitte ntly, and w ill consider stoppi ng either one, or both, arms if the s afety prof ile is 
unacceptable . The  committee w ill m eet together and review rates of deaths, SA Es, and 
progressions approx imatel y every 2 months unti l all subj ects have been accrued. A written 
committe e charter w ill provide guidance regarding m eeting conduct; t he DCRI statistician a nd 
the m eeting  Cha ir will jointl y prepare s ummary minutes from  each m eeting  and ci rculate f or 
review by the c ommittee me mbers. 
 
 
8    LI ST OF  REFERENCES  
 
1. Boyle P: Triple-nega tive b reast  canc er: epide miolog ical considerations a nd 
recommenda tions. [Internet]. Ann Oncol 23 Suppl 6:vi7–12, 2012. 
 
2. Dent R, Trudeau M, Pritchar d KI, et al: Triple-nega tive b reast cancer: clinical feature s and 
patterns of r ecurrence. Clin Cancer Res 13:4429–4434, 2007. 
 
3. Gennari A, Stockler M, Puntoni M, et al: Du ration of chemotherap y for metasta tic breast 
cancer : a sy stematic review and meta-analysis of randomiz ed clinical tria ls. J Clin Onc ol 
29:2144–2149, 2011 
 
4. Leder mann J, Harter P, Gourley C, et al: Olapar ib maintenance therapy in patients w ith 
platinum-sens itive relapsed s erous ovar ian can cer: a pre planned retrospective analysis of 
outcomes by B RCA status in a randomiz ed pha se 2 trial. Lancet Oncol 15:852–861, 2014. 
 
5. Led ermann J, Harter P, Gourley C, et al: Olapar ib maintenance therapy in platinum-se nsitive 
relapsed ov arian canc er. [Int ernet]. N Engl J Med 366:1382–1392, 2012. 
 
6. Atchley DP, Albar racin C T, Lopez A, et al: Clinical and pathologic ch aracteristics of patient s 
with BRCA-pos itive and B RCA-nega tive breast cancer J Clin Oncol 26:4282–4288, 2008. 
 
7. Ander s CK, C arey LA: Biol ogy, meta static patterns, and t reatme nt of pa tients with triple- 
negative brea st cancer. Clin B reast  Cancer 9 Suppl 2:S 73–81, 2009. 
 
8. Sor lie T, Tibshi rani R, P arker J, et al: Repea ted obs ervation of br east tumor subtypes i n 
independent gene expre ssion data set s. Proc Natl Acad Sci U S A 100:8418–8423, 2003. 
 
9. Loi S, Sirta ine N,  Piette F, et a l: Prognostic and pre dictive v alue of tumor-inf iltrating 
lymphocytes in a pha se III rando mized adjuvant breast  cancer trial in node-positive brea st 
cancer compar ing the addition of docetaxel to doxorubicin w ith doxorubicin-beas ed 
chemotherapy: BIG 02-98. J C lin Oncol 31:860–867, 2013. 
 
10. Adams S, Gray RJ, Dem aria S, et al: Prognost ic value of tumor- infiltrating lymphocytes in 
triple-nega tive brea st cancer s from two pha se III randomiz ed adjuvant breast  cancer trial s: 
ECOG 2197 and ECOG 1199. J C lin Oncol 32:2959–2966, 2014. 
 
11. Denkert C, Loibl S, Noske A, et al: Tumor-a ssociated lymphocytes as an independe nt 
predictor of response to neoadjuvant chemotherapy in brea st cancer. J Clin Oncol 28:105–113, 
2010. 
70(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
12. Loi S, Sirta ine N, Pie tte F, et a l: Prognostic and pre dictive v alue of tumo r-infiltrating 
lymphocytes in a pha se III randomiz ed adjuvant breast  cancer trial in node-pos itive brea st 
cancer compar ing the addition of docetaxel to doxorubicin w ith doxorubicin-bas ed 
chemotherapy: BIG 02-98. J C lin Oncol 31:860–867, 2013. 
 
13. Scha lper KA, Velcheti V, C arvajal D, et a l: In situ tumor PD-L1 mRNA expre ssion i s 
associated w ith increased T ILs and be tter outcome in breast  carcinomas. Clin Cancer R es 
20:2773–82, 2014. 
 
14. M ittendor f  EA, Philips AV, M eric-Bernstam F, et a l: PD-L1 expre ssion in triple-nega tive 
breast  cancer. Cancer Immunol Res 2:361–370, 2014. 
 
15. Evers B, Schut E,  van der Burg E, et al. A high-throughput ph armaceutical scr een identifie s 
compounds w ith specific toxicity against B RCA2-def icient tumor s. Clin Cancer Res 16:99– 
108; 2010. 
 
16. Farmer H, McCabe N, Lord CJ, et al: Targe ting the DNA repair defect in B RCA mutant 
cells a s a therapeuti c strategy. Nature 434:917–921; 2005. 
 
17. Bryant H E, Schultz N, Thomas HD, et al: Sp ecific killing  of B RCA2-def icient tumo rs with 
inhibitors of poly (ADP-ribose) polym erase. Nature 434;913–917; 2005. 
 
18. McCabe N, Turner NC, Lord CJ, et al. Deficienc y in the repair of DNA da mage b y 
homologous recombination and sens itivity to poly (ADP-ribose) polymerase inhibition. Cancer 
Res 66:8109–8115; 2006. 
 
19.  Menear  KA,  Adcock  C,  Boulte r  R,  e t  al.  4-[3-(4-cy clopropanec arbonylpip erazi ne- 
1-carbonyl)-4-fluorobenzyl]-2H-phthala zin-1-one: a novel bioava ilable inhibitor of poly(ADP- 
ribose) polym erase-1. J Med Chem 51:6581–6591; 2008. 
 
20. Kim G, Ison G, McKee AE, et al. FDA approval summary: olaparib monoth erapy in pa tients 
with delet erious ger mline  BRCA-mutated advanced ovar ian cancer t reated w ith thre e or mor e 
lines of chemotherapy. Clin Cancer Res 21:4257–4261; 2015. 
 
21. Dent R, Trudeau M, Pritchar d KI, et al . Triple-nega tive b reast  cancer: clinical feature s and 
patterns of r ecurrence. Clin Cancer Res 13:4429–4434; 2007. 
 
22. Lee E, McKean-Cowdin R, Ma H, et al. Char acteristics of tr iple-negative breast  cancer i n 
patients w ith a BRCA1 mutation: results from a popula tion-based study of young women. J C lin 
Oncol 29:4373–4380; 2011. 
 
23. Lehmann BD1, Bauer JA, Chen X, et al. Identifi cation of human triple-nega tive breast 
cancer subtype s  and preclini cal models f or  sel ection of  targeted ther apies. J  Clin Inve st 
12:2750–2767; 2011. 
 
24. Denkert C, von Minckw itz G, B rase JC, et al. Tumor-inf iltrating lymphocytes and response 
to neoadjuvant chemotherap y with or w ithout carbopla tin in human epid ermal growth fact or 
receptor 2-pos itive and triple-nega tive pr imary brea st cancer s. J Clin Onc ol 33:983–991; 2015. 
 
71(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
 25. Loi S, Sirtaine N, Pie tte F, et al. Prognos tic and pre dictive v alue of tumor- infiltrating 
lymphocytes in a pha se III randomiz ed adjuvant breast  cancer trial in node-pos itive brea st 
cancer compar ing the addition of docetaxel to doxorubicin w ith doxorubicin-bas ed 
chemotherapy: BIG 02-98. J C lin Oncol 31:860–867; 2013. 
 
26. Nanda R, Chow LQ, Dees EC, et al. Pembroliz umab in pa tients with advanced triple- 
negative brea st cancer: Pha se Ib KEYN OTE -012 Study. J Clin Oncol 34:2460–2467. 2016 [E- 
publish ed ahead of print] 
 
27. Nanda R, Chow L Q, Dees EC, et al. A phase Ib study of pembroliz umab (MK-3475) in 
patients w ith advanced triple-nega tive br east canc er. SABCS 2014; Abstract S1–09. 
 
28. Emens LA, Bra iteh FS, Ca ssier P, et al. Inhibition of PD-L1 by MPDL3280A l eads to 
clinical ac tivity in patients with meta static triple-nega tive breast  cancer (TNBC). Presented at 
the Am erican A ssocia tion for Cancer Research Annual M eeting; April 18–22, 2015; 
Philadelphia. Abst ract 2859. 
 
29. Ng C M, Lum BL, G imenez V, et al. Ra tional e for fixed dosing of pertuzumab in cancer 
patients based on population phar macokine tic analysi s. Phar m Re s. 2006;23(6):1275–84. 
 
 
 
30. Wang DD, Zhang S, Zhao H, et al. Fixed dosing ver sus bod y size based dosing of 
monoclonal antibodies in adult c linical trial s. J Clin Phar macol. 2009;49(9):1012–24. 
 
31. Zhan g S, Shi R, Li C, et al. Fixed dosing v ersus body s ize-based dosing of th erapeuti c 
peptides and proteins in adults.  J Clin Phar macol. 2012;52(1):18–28. 
 
32. Narwal R, Roskos LK, Robbie GJ et al. P opulation Phar macokinetic s of Sifalimumab, an 
Investigational Anti-In terferonalpha Monoclonal Antibody, in Syste mic Lupus Erythematosus. 
Clin Phar macokinet. 2013 52:1017–1027. 
 
33. Lee J M, Dos Santos Z imme r A, Lipkow itz S, et al.; Pha se I stud y of the PD-L1 inhibitor , 
durvalumab ( MEDI4736; D) in combina tion w ith a PARP inhibitor, olapar ib (O) or a VEGF R 
inhibitor, cediranib (C) in women's cancers ([STUDY_ID_REMOVED]). J Clin Oncol 34, 2016 (suppl ; abstr 
3015) 
 
34. O’Shaughness y J, Schwar tzberg L, Danso MA, et al. Pha se III study of inipar ib plus 
gemc itabine and c arbopla tin ver sus gemc itabine and carbopla tin in pa tients wi th metasta tic 
triple-nega tive breast cancer. J Clin Oncol 32:3840–3847, 2014. 
 
35. Tutt A, Tovey H, Ch eang MC et al. C arboplatin in B RCA1.2 mutated and triple-nega tive 
breast  cancer B RCAne ss subgroups: the TNT Tr ial. Nature Med 24(5):628-637, 2018. 
 
36. Seymour L, Boga erts J, P errone A, et al on behalf of the RECIST working group. iRECIS T: 
guide lines for response cr iteria for use in trials testing immuno therapeutics. Lancet Oncol 2017; 
18(3):e143-152. 
72(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
9 APPENDIC ES 
 
Appendix A : Sche dule of A ssessments 
 
Extension period – pl ease refer to  sections 4.5.2 and 4.5.3 for data to be entered in eCRF.   
 
SCHEDULE OF ASSESSMENTS 
Procedures Screeningp Cycle 1 
(q28) Cycle 2 
(q28) 
onwards End of  
treatment Follow-up 
 Within 14 
days D1  D1 (+/- 3 
days) Within 30 
days Every 8 
weeks 
(+/- 7 day s) 
Informed conse nt X      
Inclusion/exclusion 
criteria check X      
Demographics X      
Past medical history 
including past cancer 
chemotherapy, 
radiotherapy and 
surgery X      
Archival tumor tissue 
sample Xb      
Tumor assessment (CT 
or MRI)c X   Xd  Xd 
Complete physical 
examination X  X X X  
Weight (with height at 
screening) X  X X   
 
 
   
 
73(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
Vital signse X Xe Xe X  
AE and toxicities X X X Xf  
Conco mitant 
medications X X X X  
ECOG performance 
status X X X X  
Hematologyg X Xn X X  
Chemistry and 
electrolyteh X Xo X X  
Liver panel 
(ALT/AST/Bil irubin)i X Xn X X  
GFR assessmentj X Xn X X  
Pregnancy  testk X     
Buccal  Swab for DNA  
analysis X     
Biomarker blood testsl  X X [after 
staging, at 
alternating 
Cycles  
3,5,7, etc]  X  
Optional tumor biopsym Xl   Xm  
If CR/PR/SD:      
Rando mization X     
Olaparib  300 mg BID daily   
If randomized to 
combination arm:       
Durvalumab IV 1500  
mg  X X   
Survival assessmentn     Xn 
NOT E: Resu lts of standard-of-care te sts or examina tions perfor med prior to obtaining informed c onsent but w ithin the screeni ng 
window (Day-14 to Day -1) may be used for the st udy. Investigations, such as CT or MRI s cans that h ave been performe d as 
part of r outine clini cal practice to assess res ponse  to plati num, can be use d as pa rt of the screening pr ocess if perfor med within 
28 days of f irst dose of study treatment. Screening a ssessmen ts are to be performed w ithin 14 days preceding cyc le 1 day 1 
unless  otherw ise noted. E xcept for cyc le 1 da y 1, all other study v isits and a ssessmen ts during the tr eatmen t period shou ld be 
performed w ithin +/- 3 days of the sche duled date. Study assess ments may be dela yed or m oved ah ead of the wi ndow to 
accomm odate holiday s, vacations and unfores een del ays. All assessmen ts and pro cedures to be performed pre-dose  unless 
otherw ise specified. 
 
a  The end of treatment v isit shou ld occur approximately 30 d ays after the la st admin istration of olapa rib or durva lumab 
74(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
which ever is discontinued la st, or until initiation of a nother therapeu tic regimen. 
 
b Archi val tissue (e ither forma lin fixed paraff in embe dded tumor speci mens or a minimum of 10 un stained para ffin slides) must 
be available prior to entry in to the study. In the absence of archi val tissue, fre sh tissue biop sy sample s, excluding cytology a nd 
fine n eedle aspiration sp ecimens are acceptabl e. 
 
c Tumor a ssessmen ts performed a ccording to REC IST version 1.1 The met hod used for a pa tient (CT or MRI) mu st be the sam e 
throughout the study. 
 
d Tumor assess ment performe d every 8 we eks starting on D ays 21-28 of Cyc le 2 and every 8 we eks (+/- 7 day s) thereafter until 
documented d isease progre ssion. The resu lts should be rev iewed prior to dosing at the n ext cycle; tumor a ssess ments should be 
performed < =7 days prio r to continuation of study treatment on Day 1 of the s ubsequen t cycle. 
 
e Includes h eart rate, sy stolic and dia stolic blood pre ssure wh ilst in a seated po sition, and temperature . On durva lumab dosing 
days, recorded prior to dosing and at the end of the infu sion. 
 
f Patients with unresol ved adverse events or seri ous ad verse events will be fo llowed un til the event is resol ved or stabilized, th e 
patient is lost to fo llow-up or it has b een determined that the study treatment or participa tion is not the cause of the event. 
 
g Includes RBC count, WBC c ount, WBC di fferential c ount (neu trophils, bands, lymphocytes, eosino phils, basoph ils, monocytes 
and other cells),  absolu te neutroph il coun t, hemogl obin, hematocrit and platelet count. 
 
h  Includes s odium, potassium, chloride, bi carbona te urea , creatinine, calcium, phosphoru s, magnesium, thyro id stimula ting 
horm one (combina tion arm only), free triiodothyronine (T3) (combina tion arm only) and free thyroxine (T4) (combina tion a rm 
only). See A ppendix G for a dditional req uired te sts for Korean sit es only. 
 
i Includes total b ilirubin, total protein, albumin, AST, A LT an d alkaline phosphatas e. 
 
j As calculated by the Co ckcroft-Gau lt formula. 
 
k For women of ch ildbearing poten tial (including t hose who h ave had a tubal ligation). For a ll other wo men, documenta tion 
must be present in medi cal h istory c onfirming the pa tients is not of ch ildbearing poten tial. 
 
l Biomarker blood sp ecimens w ill be co llected at v isit C1D1, D1 after each staging cycle (C3D1, C5D1, C7 D1 etc), and End of 
Treatment (EOT). 
 
m Tumor biop sy collection is optional for study participa tion if archi val tissue is available. For pa tients who c onsent for tumor 
biopsy , this will be co llected prio r to treatmen t, and/or during inter val of c linical res ponse, a t the time of progre ssion and/or a t 
the end of the study. 
 
n Informa tion a bout survival and s ubsequent anti-can cer therapies will be co llected v ia telephone calls, patient medi cal record s 
and or c linic visits approximately every 8 weeks until death, lo ss to follow-up, or study termina tion unle ss the pa tient req uests to  
be w ithdraw n from fo llow-up; th is request must be documented and signed by the in vestigator. 
 
o Where l aborato ry investigations have not b een performed w ithin the 7-day period prior to starting treatment, they mu st be 
repeated on day 1 of cycle. 
 
P ECG is required at screening for Korean sit es only . See A ppendix G. 
75(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
Appendix B : Known S trong i n Vivo I nhibitors or I nducers of CYP3A  
 
Strong  Inhibitors of CYP3Aa Strong  Induc ers of CYP3Ae 
Bocep revir carbamazepinef 
clarithromycinb phen ytoinf 
conivaptinb rifampinf 
grapefruit juicec St John's wortf 
indinavir  
itraconazoleb  
ketocona zoleb  
lopinavir/ritonavirb (combination drug)  
mibefradild  
nefazodone  
nelfinavir  
posac onazole  
ritonavirb  
saquinavir  
telaprevir  
telithromycin  
voricona zole  
Source: 
FDA Drug De velopment and Drug Interactions:  Table of Sub strates, Inhibitors and Inducers.  Web link Ac cessed 21 Ja nuary 
2015: 
http://ww w.fda.gov /Drugs/Devel opmentA pprovalProcess/Develo pmentResources/Dr ugInteractionsLabe ling/ucm 093664 .htm 
#inVi vo 
Note: The list of drug s in these tables is not exhaustive. Any questions about drug s not on th is list should be addressed to the 
Study Cha ir of the protoco l. 
a. A strong i nhibitor for CYP3A i s defined as an inhib itor that increa ses the A UC of a s ubstr ate for CYP3A by ≥ 5-fol d. 
b. In vivo inhib itor of P-glyc oprotei n. 
c. The eff ec t of grapefru it juice varies wide ly among bra nds and is concen tration-, dose-, and prepara tion-dep endent. Studies 
have shown that it can be cla ssified as a “ strong CYP3A inhibitor” whe n a certa in prepara tion wa s used (eg, high dos e, 
doub le strength) or as a “m oderate CY P3A inhibitor” whe n another prepara tion was used (eg , low dose, single strength). 
d. W ithdrawn from the Un ited States market b ecause of safety reas ons. 
e. A strong inducer f or CYP3A is  defined as an inducer that results in ≥ 80% de crease in the AUC of a 
substrate for CYP3 A. 
f. In vivo indu cer of P-gl ycoprotei n. 
76(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
Appendix C : Adverse  Event Assess ment of Causality  
 
Is there a reasonable possibility that t he event may have been caused by stud y 
drugs ? No   Y es   
 
The descriptions provided below w ill help guide the principal inve stigator in making 
the decision to choose either “yes” or “no ”: 
 
No = There is no reasonable possibility that the event may have b een caused b y 
study drug s. 
 
The adver se event: 
• may be judged to be due to ext raneous causes such as dis ease or 
environment or toxic factors 
• may be judged to be due to the subj ect’s clinical state or other the rapy bei ng 
administered 
• is not biologi cally plausible 
• does not reapp ear or worsen when study drug is re-a dministered 
• does not foll ow a tempora l sequence from administ ration of study drug 
 
Yes = There is a reaso nable possibility that the event may have been caused b y 
study drug s. 
 
The adver se event: 
• follows a tempora l sequence from administ ration of study drug 
• is a known re sponse to the study drug based on clini cal or preclinical da ta 
• could not be explained by the known cha racte ristics of the subj ect’s c linical 
state, environmental or t oxic factor s, or other therapy administered to t he 
subject 
• disappear s or dec reases upon cessa tion or reduction of dose of study dr ug 
• reappe ars or wor sens when study drug is r e-administ ered 
77(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
Appendix D : U nder 30 kg Total Body Weight Durvalu mab Dose calc ulation  
Dose Calcula ti ons ON LY for subj ects 30kg body weight and under .  ALL subje cts over 30k g 
total body weight are given fixed dosing of 1500mg every 4 w eeks (see sec tion 1.5.2) 
 
1. Or dered dose: 20 mg/ kg 
 
 
2. Subj ect weight: X kg 
 
 
3. Dose for subje ct: Y mg = 20 (mg/ kg) × X (kg) 
 
 
4. Dose to be added into infusion bag: 
 
 
Dose (mL) = Y m g/50 (mg/mL) where 50 mg /mL is durvalumab nominal concentra tion. 
 
 
The corresponding volume of durvalumab should be rounded to the nea rest tenth mL (0.1 mL). 
Dose adjus tments for each cy cle are only needed for g reater than 10% change in weight. 
 
5. The theore tical number of vials required for dose pre paration is the next g reate st whole 
number of vials from the following formula: 
 
Num
ber of vials = Dose (mL)/10.0 (mL/vial) 
 
Examp le for 30kg subject dosing at 20mg/kg every 4 weeks:  
 
1. Or dered dose: 20 mg/ kg every 4 w eeks 
 
 
2. Subj ect weight: 30 kg 
 
 
3. Dose for subje ct: 600 mg = 20 (mg/kg) × 30 (kg) 
 
 
4. Dose to be added into infusion bag: Dose (mL) = 600 mg/50 (mg/mL) = 12.0 mL 
 
 
5. The theore tical number of vials required for dose pre paration: 
Number of vials = 12.0 (mL)/10.0 (mL/vial) = 2 vials 
(provided by Astra Zene ca) 
78(80) Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0  
  
 
 
Appendix E : A ssessment of Poss ible Drug Induced Liver Inju ry 
 
The followi ng assessmen ts are to be reported in the c linical database , utili zing Comment 
Form as ne cessary for additional informa tion. 
 
• Subj ect’s age, sex, we ight, and height 
 
• Signs and symptoms related to hepatotoxicity: type and timing  to exposure 
 
• Rela tionship of exposure dura tion and dose to the development of the liver injury 
 
• Pertinent medi cal history • Concomitant drug s with dates and doses • P ertinent physi cal 
exam f indin gs 
 
•
 Test results (e.g., labor atory data, biopsy data and reports, with dates and normal ranges) 
 
• Time cour se of serum enzyme and bilirubin eleva tions (consider tabular a nd/or graphi cal 
display of serial labora tory data) 
 
• A su mmary of all available c linical informa tion including, if known: 
 
− Prior or cur rent histo ry of e thanol use 
 
− Presence of r isk facto rs for NASH (e.g., obe sity, diabete s, marked 
hypertriglyc eridemia) 16 Contains Nonbindi ng Recommenda tions 
 
− Evid ence for pre- or co-exis ting vi ral hepa titis, or other forms of liver disease, pre study 
AT value s, if ava ilable 
 
− Symptoms  and c linical cour se including follow-up to resolution − Special studies ( i.e., 
ultrasound, radiologic exa mina tions, liver biopsy result s) 
 
− Presence or absence of possible confounder s, including conc omitant illness, use of 
concomitant drug s that are known hepatotoxins, such as aceta minophen 
 
• Treatment provided 
 
• Decha llenge and r echallenge results, if done 
 
• Outcomes and follow-up informa tion 
 
• The site should al so supply re dacted copies of available hospital discharge summar ies, 
pathology and autopsy reports 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
79(80)  
  
 
 
 
Appendix F : Toxicity Management G uidelines Durvalumab  
 
These guidelines are now provided to sites as a separate document.  
 
 
80(80)  
 Phase II Multicenter Study of Durvalumab and Olaparib in platinum t Reated Advanced triple neg ative brea st cancer 
V 6.0 
 
  
 
 
Appendix G : A dditional requi red tests (Ko rean si tes ONLY)  
  
 
4.1.2 S creening Procedures  
 
• 12 l ead resting ECG 
• Amylase, Lipase, GGT (ga mma glutamyl t ransferase), Urinaly sis 
 
4.5.1 During olapar ib or olaparib and durvalumab maintenance 
 
• Amylase, Lipa se 
• As clinically indicated: GGT,  Urinalysis 
 
4.5.2 Subsequent vis its (and Table 7. Cli nical che mistry S erum or Plasma Laboratory Test s) 
 
• Amylase, Lipa se 
• As clinically indicated: GGT,  Urinalysis 
 
 
 
 
Urinalysis Te stsa 
 
Bilirubin 
Blood 
Gluc ose 
Ketones 
pH Prote in 
Specific g ravity 
 
Colour and appea rance 
 
a Microscopy should be used as appropriate to inves tigate whit e blood ce lls and use the high 
powe r field for red blood cells 
 
 
 
 
  
 
  
 
  
 